WELL, WELCOME TO THIS GATHERING
OF THE 310th GATHERING OF THE
NATIONAL HEART LUNG AND BLOOD
INSTITUTE.
WE APPRECIATE YOUR COUNCIL,
SHARING THEIR WISDOM AND THEIR
TIME WITH US AS PART OF THEIR
DELIBERATIONS AND WITHOUT
FURTHER ADO LET ME TURN IT OVER
TO OUR EXECUTIVE SECRETARY
DR. CHARISEE LAMAR AND CALL US
TO ORDER.
>> THANK YOU DR. GIBBONS.
GOOD MORNING AND WELCOME
EVERYONE.
THIS 310th MEETING OF THE
ADVISORY MEETING OPEN SESSION,
NOTICE WAS PUBLISHED IN THE
FEDERAL REGISTER, THE MEETING IS
BEING RECORDED AND THE VIDEO
WILL BE ARCHIVED AND REMAIN
AVAILABLE TO THE PUBLIC AND NIH
COLLEAGUES.
AS WE REVIEW OUR AGENDA ITEMS
TODAY, WE WILL START OFF AFTER
MY ADMINISTRATE OF ANNOUNCEMENTS
WITH THE DIRECTOR'S REPORT, WE
WILL HAVE A 30 MINUTE BREAK FOR
LUNCH, WE WILL HAVE THE
TRIENNIAL REPORT INCLUSION
REPORT FOLLOWED BY A
PRESENTATION NIH CIT ENABLING
ACCESS AND INNOVATION WITH
ADVANCED TECHNOLOGY.
I WILL GIVE AN OVER VIEW OF
TEABING AN NHLBI AI WORKING
GROUP AND THEN I WILL ALSO
FOLLOW UP WITH THE REVIEW AND
AUTHORITY DELEGATIONS OF AI AND
THEN WE WILL HAVE A BRIEF
DISCUSSION AND FOLLOW WITH
ADJOURNMENT.
SO WITH THAT, AND WITHOUT
FURTHER ADO, WE WILL MOVE TO THE
DIRECTOR'S REPORT WITH
DR. GIBBONS.
>> CAN YOU HEAR ME OKAY?
>> YES.
>> NEXT SLIDE, PLEASE.
NEXT SLIDE, PLEASE.
SO FIRST OUR ACCOUNTABLE
STEWARDSHIP UPDATE.
AS YOU'RE AWARE, CONGRESS IS PUT
IN A FULL YEAR CONTINUING
RESOLUTION.
THIS IS A BIT UNUSUAL THAT WE
DON'T HAVE A FORMAL
APPROPRIATION IN FY25 AND SO
IT'S BASICALLY CONTINUES THE
GUIDANCE FROM CONGRESS FROM 24
AND EXTENDS IT TO 25.
AND SO WE'RE FLAT, RELATIVELY
SPEAKING TO THAT 24 MARK.
AND WE'RE SIDE WE HAVE A GREAT
OPPORTUNITY TO EMBRACE NEW
LEADERSHIP OF DIVISION OF
CARDIOVASCULAR SCIENCES AND
WE'RE GRATEFUL THAT THESE
LEADERS ARE STEPPING UP INTO
THIS CHALLENGE AND OPPORTUNITY,
APPRECIATE IN PARTICULAR
DR. GINA WEI WHO IS SERVING AS
ACTING DIRECTOR AS WE PURSUE A
NATIONAL SEARCH FOR THAT, AND
SHE'S JOINED BY A GREAT
LEADERSHIP TEAM THAT YOU SEE
HERE WHO ARE FILLING IN THE
ASSOCIATE DIRECTOR ROLES
DR. SACHDEV AND REDMONITORED AND
OLIVE ARE AGAIN PROVIDING
IMPORTANT STEWARDSHIP AND
LEADERSHIP.
NEXT SLIDE, PLEASE.
TOWARD THAT END LET ME PIVOT TO
THE SCIENTIFIC PRIORITIES.
NEXT SLIDE IN WHICH WE CONTINUE
TO PURSUE A LOT OF OUR ENDURING
PRINCIPLES AS WE BEGIN TO REALLY
LAUNCH THE STRATEGIC VISION
REFRESH.
THAT'S IN ITS FINAL STAGES AND
WE WILL BE, I BELIEVE, RELEASED
SOON IN THE NEXT COUPLE OF
MONTHS THAT WE ARE HAVE BEEN
PARTICIPATING IN WITH COUNCIL
AND THE COMMUNITY TO SHAPE THAT
AND SO I THINK WHAT YOU WILL
FIND AS YOU SEE THAT FINAL
PRODUCT, IS IN MANY WAYS A
REAFFIRMATION OF THE STRATEGIC
VISION GOALS, OF UNDERSTANDING
HUMAN BIOLOGY, REDUCING HUMAN
DISEASE, DEVELOPING A WORKFORCE
AND RESOURCES AND ADVANCING THE
TRANSLATION OF THAT RESEARCH TO
HAVE HIGH HEALTH IMPACT AND
PROVIDE THE HEALTH FOR ALL.
AND THAT WAY CONTINUING WITH OUR
ENDURING PRINCIPLES AND OUR
MISSION THAT WE BELIEVE IS WELL
ALIGNED WITH THE NEW
ADMINISTRATION AS IT HAS BEEN
WITH PRIOR ADMINISTRATIONS
INCLUDING THE FIRST VERSION OF
ITS ADMINISTRATION.
SO WE'RE VERY EXCITED TO ALIGN
WITH THOSE AGENDAS, PARTICULARLY
TO THE DEGREE TO WHICH WE
UNDERSTAND AN EMPHASIS ON
ADDRESSING THE EMERGING
CHALLENGES OF CHRONIC DISEASE
AND OBVIOUSLY THAT'S BEEN AN
ESSENTIAL PART OF THE MISSION OF
NHLBI FOR THE LAST 75 YEARS
THROUGH MANY ADMINISTRATIONS AND
THEREFORE WE ARE CONFIDENT AND
QUITE OPTIMISTIC THAT MOVING
FORWARD WE CAN CONTINUE TO
PURSUE THAT RESEARCH AGENDA WITH
ALIGNMENT OF RESEARCH PRIORITIES
THAT ARE IN OUR STRATEGIC VISION
REFRESH IN PARTICULAR JUST TO
HIGHLIGHT A COUPLE OF THEMES OF
ENHANCING HEART LUNG AND BLOOD
SLEEP, HEALTH THROUGH PREVENTION
AND EARLIER INTERVENTION, I
BELIEVE IS VERY CONSISTENT WITH
NOT ONLY THE PRIORITIES OF PRIOR
ADMINISTRATIONS BUT THIS 1 AS
WELL.
AND WE LOOK FORWARD TO EMBRACING
THE CHALLENGE AND OPPORTUNITY OF
A CONCEPT THAT WE'VE BEEN
PURSUING FOR THE LAST REALLY 10
YEARS TO PREEMPT CHRONIC DISEASE
THROUGH INTEGRATED SYSTEMS
BIOLOGY AND NEW TECHNOLOGIES OF
INNOVATION PARTICULARLY WITH AI
SUCH THAT WE ARE ABLE TO DETECT
DISEASE ACROSS CRON NICK
DISORDERS IN THE SPEBLGHT RUM,
SO WE BELIEVE IN MANY WAYS OUR
ENDURING PRINCIPLES AND
STRATEGIC GOALS AND MISSIONS ARE
IN LIEN WITH THE NEW ADMISSION
AND THE NEW DIRECTOR TALKED TO
US WITH THAT VISION.
NEXT SLIDE, PLEASE.
TOWARD THAT END WE ALWAYS FOCUS
ON THE SCIENCE AND THE DATA TO
DRIVE OUR PRIORITIES BOTH
RECOGNIZING THE CRITICAL
CHALLENGES, THE COMPELLING
QUESTIONS, MOST IMPORTANTLY THE
OPPORTUNITY AND SO IT HAS BEEN
NOTED THAT THE UNITED STATES OUR
ONGOING AND GROWTH LIFE
EXPECTANCY THAT'S GONE ON FOR
DECADES QUITE FRANKLY REFLECTIVE
OF PRIOR INVEST AMS IN NIH
FUNDED RESEARCH HAS DRIVEN THAT
LIFE EXPECTANCY RISE AND
RECOGNIZE THAT THERE HAS BEEN AN
INCREASING GAP WITH NATIONS OF
COMPARABLE WEALTH AND INCOME AND
DEVELOPMENT.
AND SO WE HAVE BEEN CONCERNED
ABOUT THAT SLOWING RATE AND
INDEED THE RECOGNITION IN MANY
COMMUNITIES AND POPULATIONS IT'S
FLATTENED OUT SIGNIFICANTLY.
AND THAT REFLECTS IN MANY CASES
THE ONSET AND COMPOUNDING
CO-MORBIDITIES OF CERTAIN
CHRONIC DISEASES AND CHRONIC
CONDITIONS WHICH OF CLEARLY
PROBABLY THE OBESITY EPIDEMIC
OVER THE LAST COUPLE OF DECADES
HAS STARTED TO MAKE THAT
CONTRIBUTION AND MANIFEST,
PARTICULARLY IN YOUNGER ADULTS.
NEXT SLIDE, PLEASE.
WHICH YOU SAW IN THE PREVIOUS
SLIDE, IN YOUNGER ADULTS IS
HAVING GREATER THAN 2 CHRONIC
CONDITIONS.
IT'S QUITE REMARKABLE SO AS WE
THINK THROUGH THAT POPULATION
AND THE VARIANCE AND
HETEROGENEITY OF THE AMERICAN
POPULATION WITH REGARD TO
ACHIEVING FURTHER EXTENSIONS OF
LIFE EXPECTANCYS, WE RECOGNIZE
THAT THERE'S QUITE A BIT OF
VARIANCE BY DEFINITE SEGMENTS OF
OUR POPULATION AND YOU CAN SEE
THAT VARIANCE AND IN PARTICULAR
SOME GROUPS WHERE IT'S CLEARLY
GOING THE WRONG DIRECTION
PARTICULARLY WITH REGARD TO THE
FIRST AMERICANS, NATIVE
AMERICANS, AMERICAN INDIAN
POPULATIONS.
CERTAINLY AFTER AMERICAN
POPULATIONS HAVE ALSO HAD
CHALLENGES IN THE RATE OF GROWTH
OF THAT LIFE EXPECTANCY CURVE.
AND SO CLEARLY THERE WILL BE A
CRITICAL NEED TO ADDRESS THIS
HETEROGENEITY AND INDEED PERHAPS
THE -- A KEY PART OF PUTTING OUR
COUNTRY BACK IN A LEADERSHIP
ROLE OF EXTENDING LIFE
EXPECTANCY AND MAKING THE
RESEARCH INVESTMENTS NECESSARY
TO SPEED AND ACCELERATE THAT
EXTENSION, WE MAY NEED TO
PARTICULARLY TARGET THOSE
COMMUNITIES AND POPULATIONS THAT
ARE LAGGING BEHIND FOR FURTHER
INTERVENTION.
NEXT SLIDE, PLEASE.
AND AGAIN WHEN IT COMES TO
HETEROGENERATED AIC DISEASE, IT
MATTERS AND THE PLACE IS EVIDENT
BY THE PREVALENCE OF THESE
VARIOUS CONDITIONS AND PERHAPS
PRECURSORS OF THIS PANDEMIC OF
CHRONIC DISEASE.
AND SO IF WE WANT OUR NATION TO
BE HEALTHIER AND HAVE THRIVING
COMMUNITIES IT BEHOOVES US BY
THE DATA TO RECOGNIZE THAT THIS
PROBABLY IS NOT REFLECTIVE OF A
STRONG GENETIC SIGNAL THAT
EXPLAINS THESE OUTCOMES AND
PROBABLY REFLECTS MORE OF THE
LOCAL CONTEXT WHETHER THAT'S
SOCIAL DETERMINANTS OF HEALTH OR
OTHER ENVIRONMENT EXPOSURES THAT
APPEARS TO BE DRIVING THESE
CHRONIC CONDITIONS AND IT'S NOTE
WORTHY THAT FOOD INSECURITY ALSO
OVERLAPS WITH THIS SUGGESTING
AGAIN SOCIAL DETERMINANTS MAY BE
CRITICAL ROOT ELEMENTS OF IT AND
RECOGNIZING THIS SORT OF
MULTILAYERED AND MULTILEVEL
CONTRIBUTIONS ALSO PROBABLY
SUGGESTS HOW WE MAY NEED TO
ADDRESS THIS IN A COMPARABLY
MULTILEVEL, MULTIPRONG WAY MAY
BE NECESSARY TO CHANGE THESE
CURVES.
NEXT SLIDES.
TOWARD THAT END, IT'S VALUABLE
TO CONSIDER THAT INNER PLAY
BETWEEN THE SUSCEPTIBILITYS TO
CHRONIC DISEASES PARTICULARLY
RELATED TO GENETIC RISK AS WE
CONTINUE TO MAKE ADVANCES IN
UNDERSTANDING THE DETERMINANTS
OF CHRONIC DISEASE AND
RECOGNIZING THE CONTRIBUTIONS OF
THE GENETIC RISK THAT THERE ARE
ALSO THOSE LIFESTYLE RISKS
FACTORS THAT ARE VERY MODIFIABLE
AND AGAIN COULD BE SOURCES OF
INTERVENTION IN A PREVENTIVE AND
PRECISION PREVENTIVE WAY AND
INDEED, YOU SEE IN THIS WORK
MANY YEARS AGO THAT INTERACTION
BETWEEN EVEN THOSE WHO ARE HIGH
GENETIC RISKS THAT MIGHT BE
MODIFIED BY THE PREVENTIBLE AND
MODIFIABLE RISK FACTORS AND
INTERVENTIONS THAT DRIVE IT.
NEXT SLIDE, PLEASE.
SO TOWARD THAT END, AS WE THINK
ABOUT HOW WE COULD CHANGE THE
DIRECTION OF THIS PANDEMIC OF
CHRONIC DISEASE IT WOULD SUGGEST
THAT THE MONEY IS GOING TO BE
MOVING EARLIER.
YES, WE WILL CONTINUE TO DEVELOP
TREATMENTS AND INNOVATE ALONG
THAT AXIS, THE OPPORTUNITY
REALLY IS TO MOVE EARLIER IN
ALMOST ALL OF OUR CHRONIC
CONDITIONS SUCH THAT WE ARE
SEEING WHO'S AT RISK, SEEING
WHO'S AT HIGHEST RISK, AND
PERHAPS TARGETING THOSE
INTERVENTIONS EARLIER AND
SELECTIVELY IN WAYS THAT CAN
CHANGE THE WHOLE TRANSLATIONAL
RESEARCH -- TRAJECTORY
OF LIFE COURSE AND CHRONIC
DISEASE AND PERHAPS CONTRIBUTE
TO ITS PREEMPTION IN SO DOING.
NEXT SLIDE, PLEASE.
SO IT'S APPRECIATING THAT SORT
OF LIFE COURSE VIEW THAT 1 OF
THE REASONS WE'RE NO LONGER
DOING CARDIOVASCULAR COHORT
STUDIES LIMITED TO 45 AND 65
THAT FRAMINGHAM SORT OF SET AS
THE MODE OF HOW WE OPERATE, WE
ARE INCREASINGLY APPRECIATING
THAT MANY OF THOSE RISKS AND
EXPOSURE REALLY OCCUR VERY EARLY
ON, PERHAPS EVEN IN UTERO,
CERTAINLY THROUGH CHILDHOOD THAT
SETS A TRAJECTORY OF CHRONIC
DISEASE THAT MAY BE MANIFESTING
IN MIDLIFE AND LATER LIFE.
AGAIN, PUSHING US TOWARD EARLIER
DETECTION AND INTERVENTION AND
IN PARTICULAR THIS IS NOTABLE
FOR WOMEN'S HEALTH AND SOME OF
OUR WOMEN'S HEALTH ACTIVITIES.
NEXT SLIDE, PLEASE.
AS YOU'RE AWARE OF OUR STUDIES,
PARTICULARLY NEW MOMS TO BE
COHORT, WHERE WE RECOGNIZE OFTEN
REG NANCY IS A SO CALLED STRESS
TEST IN WHICH WE RECOGNIZE THAT
THE DEVELOPMENT FOR EXAMPLE
GUESTATIONAL DIABETES,
FORESHADOWS THE POETIC TEBTICAL
OF THAT INDIVIDUAL EVEN POST
PREGNANCY TO DEVELOP
HYPERTENSION OR DIABETES AND
CLEARLY THERE'S ALSO A
RELATIONSHIP BETWEEN THE
PREGNANCY COMPLICATIONS AND
THEIR IMPLICATIONS ON
DEVELOPMENT OF CHRONIC
CONDITIONS MUCH LATER AND HERE
YOU CAN SEE SOME OF THE DATA
FROM NEW MOMS TO BE THAT STARTS
TO SET THAT IN MOTION.
NOT ONLY FOR THE MOM BUT FOR THE
CHILDREN AS WELL, AND SO,
CHILDREN BORN TO MOTHERS WITH
HIGH BLOOD PRESSURE IN PREGNANCY
ARE AT HIGHER RISK THEMSELVES.
THEY HAVE AN EARLY ONSET OF
PROBLEMS WITH BLOOD PRESSURE AND
CARDIOVASCULAR DISEASE, SO IT'S
ALMOST THIS INTERGENERATIONAL
ELEMENT THAT IS PART OF THAT
LIFE SPAN TRAJECTORY AND IS
SUGGESTIVE OF A POTENTIAL TO
ACTUALLY INTERVENE IN WAYS THAT
WILL HELP BOTH BABY AND MOM IN
MULTIPLE WAYS OVERTIME.
NEXT SLIDE, PLEASE.
AND TOWARD THAT END, WE'RE
ALREADY AGAIN THANKS TO NEW MOMS
TO BE, GETTING TO THAT
CONVERGENCE OF UNDERSTANDING
WHAT ARE THOSE SUSCEPTIBILITY
FACTOR, TYPICALLY GENETIC THAT
MAY PLAY A ROLE HERE AND AGAIN,
VERY INTRIGUING OBSERVATIONS
ABOUT IDENTIFYING POLYGENIC RISK
SCORES AND GENETIC LOCI
ASSOCIATE WIDE PREELAMPSIA,
ECLAMPSIA OR GUESTATIONAL
HYPERTENSION AND IT'S INTRIGUING
THAT A LOT OF THOASES LOCI ALSO
CROSS WALK TO THOSE OF PRIMARY
HYPERTENSION SEPARATE FROM
PREGNANCY.
SUGGESTING AGAIN THAT A STRESS
TEST FOR THOSE WHO MIGHT BE
GENETICALLY SUSCEPTIBLE TO
CHRONIC PRIMARY HYPERTENSION AND
INDEED THAT GENETIC RISK FACTOR,
NEXT SLIDE, PLEASE, COULD BE
HELPFUL AS A DETERMINING RISK IN
A PRECISION WAY BUT ALSO LET ME
BE COMPLEMENTED BY INTERVENTIONS
THAT WE CAN DO, SOME OF WHICH
THAT THEY RELATE TO LIFESTYLE
AND BEHAVIORIAL CHOICES.
SO WE'RE VERY EXCITED ABOUT THE
ROLL OUT OF THE ENRICH STUDY,
WHICH REALLY STARTS TO TARGET
POPULATIONS AT HIGHEST RISK.
I BELIEVE THIS IS AN EXAMPLE
FROM MOTHERS AND CHILDREN IN
NORTHERN APPALACHIA AND SO IT'S
THAT HEART LAND WHERE WE SAW
THAT CONCENTRATION OF BOTH RISK,
CHRONIC DISEASE, AND MATERNAL
MORTALITY AND THIS TEST AN
INTERVENTION OF OF HOME VISITS
WHERE THOSE LIFESTYLE MODIIVESS
EVEN LEVERAGING THE SIMPLE 7 OF
AHA IS A MEANS TO ENGAGE REALLY
THE FAMILY, MOM, CHILD IN WAYS
THAT HOPEFULLY CAN BE SUSTAINED
WHERE THEY'RE GIVING HEART
HEALTHY DIETS AND ACTIVITY AND
LIFESTYLE THAT BEGINS LITERALLY
AT DAY 1 AND WE'RE HOPEFUL THAT
NOT ONLY THIS HAS A SHORT-TERM
BENEFIT BUT HOPEFULLY WE'RE
STARTING TO MODIFY THE
TRAJECTORY OF BOTH MOM AND
CHILDREN.
INDEED IT'S EXEMPLAR OF THE KIND
OF EARLY INTERVENTIONS THAT WE
MAY NEED TO PURSUE AND TEST.
NEXT SLIDE, PLEASE.
PARTICULARLY TARGETED TO CERTAIN
POPULATIONS, INDEED MAYBE IT'S A
FORERUNNER OF OTHER
INTERVENTIONS THAT WE'VE
ESTABLISHED THAT RISK AGAIN,
WE'RE VERY EXCITED ABOUT THE
RESULTS OF THE CHAP STUDY THAT
SHOWED TREATING HYPER ATTENTION
DURING PREGNANCYY MORE
AGGRESSIVELY YIELDED BENEFITS IN
TERMS OF REDUCING THE FREQUENCY
OF PREECLAMPSIA AND WITHOUT HARM
TO THE BABY IN WAYS THAT WE HOPE
CAN HAVE LONG-TERM BENEFITS
AGAIN FOR BOTH MOM AND BABY AND
TOWARD THAT END, WE'RE EXCITED
THAT THOSE ARE NOW IN
GUIDELINES.
I THINK THE GUIDELINES CHANGED
WITHIN A MONTH OF THIS TRIAL
RESULT.
NEXT SLIDE.
SO IN THAT REGARD, WE HAVE AN
OPPORTUNITY TO INTERVENE AND
EVEN IN PRIMARY CARE SETTINGS,
NEXT SLIDE, IN WHICH WE TART TO
TAKE CARE OF WOMEN ACROSS THE
LIFE SPAN, BOTH BEFORE, DURING
AND AFTER PREGNANCY AND IN SOME
WAYS TO CHANGE THAT TRAJECTORY.
THAT SUGGESTS THAT WE NEED TO
BREAK THOSE LINES BETWEEN THE
OBSTETRICIAN AND THE PRIMARY
CARE, ET CETERA AND INDEED, IF
INDEED WE'RE TREATING AND CARING
FOR THESE WOMEN OF REPRODUCTIVE
AGE, WELL BEFORE THEY GET
PREGNANT WE MAY FIND THAT A LOT
OF THOSE PREGNANCY OUTCOMES CAN
IMPROVE AND IT'S REALLY
CHALLENGED US TO THINK ABOUT
PARTICULARLY IN THESE VULNERABLE
COMMUNITIES AND VULNERABLE
POPULATIONS CAN WE HAVE A BRIDGE
THAT PROMOTES A HEALTHY LIFE AND
THRIVING COMMUNITIES WHERE THEY
HAVE ACCESS TO THAT HEALTHY
LIFESTYLE.
AND THIS IS AN OPPORTUNITY TO
LEVERAGE A PLATFORM OF OUR
COMMUNITY ENGAGED ALLIANCE, THAT
IS NOW NO LONGER FOCUSED ON
COVID BUT IT REALLY FOCUSED AS A
PLATFORM THAT IS INCLUSIVE OF A
VARIETY OF CONDITIONS THAT ARE
PREVALENT WITHIN THAT COMMUNITY
AND PRIORITIZE FOR INTERVENTION
BY THAT COMMUNITY AND THEN THAT
WAYS DISEASE AGNOSTIC IF YOU
WILL OR INCLUSIVE AND THAT THIS
IS A PLATFORM THAT NOT ONLY
INCLUDES HEART LUNG AND BLOOD
SLEEP DISORDERS BUT IT GOES
ACROSS THE FULL SPECTRUM OF THE
NIH PORTFOLIO RELEVANT TO THESE
COMMUNITIES IN A WAY THAT'S MORE
ADAPTIVE TO THEIR PRIORITIES AND
THEIR NEEDS IN A WHOLISTIC AND
COMPREHENSIVE FASHION SO WE'RE
BUILDING UPON THIS STRUCTURE AND
THE CEAL ALLIANCE IS TARGETED
TOWARD THE MOST VULNERABLE
COMMUNITIES, NOT ONLY MOST
VULNERABLE TO COVID BUT CHRONIC
CONDITIONS IN FACTEE RELATED TO
MANY OF THOSE SOCIAL
DETERMINANTS THAT ARE SO HIGHLY
PREVALENT IN THOSE COMMUNITIES.
AND SO WE SEE THIS AS AN IDEAL
PIVOT AND PLATFORM, THAT COULD
BE REALLY INSTRUMENTAL IN
ADDRESSING THE PANDEMIC OF
CHRONIC DISEASE NEXT SLIDE,
PLEASE.
IN THAT REGARD, THE TEAM HAS
ALREADY ENGAGED COMMUNITIES AND
PLATFORMS FOR INFORMATION
SHARING AND PREVENTION TO LINK
TO PRIMARY CARE NETWORKS
NETWORKS SO THAT
WAS THE VISION FOR CREATING CEAL
CARE NET BOTH INSIDE AND OUTSIDE
THE CLINIC WALLS WITHIN THESE
COMMUNITIES SUCH THAT WELL IS
THAT CONTINUITY AND AN
OPPORTUNITY TO DO MULTILEVEL
INTERVENTIONS AND SO MANY OF
THEM DO HAVE QUALIFIED HEALTH
CENTERS AND THE CITRUS GROUP AND
THE CEAL TEAM VS STARTED WITH A
COUPLE OF PRIMARY CARE BASED
RESEARCH NETWORKS AS PART OF
THAT STUDY WITH THE OVERLAP
SHOWN HERE WITH THE CEAL TEAMS,
NEXT SLIDE, PLEASE AND INDEED WE
ARE TO CREATE A MORE SEAMLESS
DATA RESOURCE AS PART OF THE
ECOSYSTEM LINKED TO THE
ELECTRONIC HEALTH RECORDS OF
THESE CLINICS EMBEDDED IN THESE
HIGH RISK COMMUNITIES SUFFERING
FROM THESE DISPARITIES OF
CHRONIC CONDITIONS.
SO WE SEE AN OPPORTUNITY TO LINK
THE CARE SETTING, THE COMMUNITY
SETTING WITH THIS DATA RESOURCE
CAPABILITY THAT COULD BE
AMINABLE TO SOME OF THE
OPPORTUNITIES IN MACHINE
LEARNING AI AND UNDERSTANDING
COMMUNITY HEALTH BETTER
LEVERAGING DATA SCIENCE
CAPABILITIES.
NEXT SLIDE, PLEASE.
IN THAT REGARD OCHIN 1 FORT
PARTNERS HAS STARTED TO USE
THESE RESOURCES TO START TO
IDENTIFY WHY IS IT THAT THERE'S
UNCONTROLLED HYPERTENSION OR
DIABETES AND CLEARLY IS PART OF
THIS THROUGH THE EHR, THEY START
TO IDENTIFY THERE WERE CERTAIN
RACIAL AND ETHNIC GROUPS THAT
WERE AT HIGHER RISK OF HAVING
UNCONTROLLED BLOOD PRESSURE.
CLEARLY SOCIAL FACTORS LIKE
INSURANCE, CO-PAYS, THE ABILITY
TO ENGAGE PROVIDERS, WHETHER
THAT'S THROUGH AN ACCESS OR
DISTANCE PERHAPS IN RURAL
COMMUNITIES, AND MAYBE ISSUES OF
HEALTH LITERACY, IF THEY'RE
NEWEL DIAGNOSED AND DON'T
APPRECIATE THE RISKS OF
UNCONTROLLED HYPERTENSION AND SO
1 OF THE CHALLENGES IF THESE ARE
THE RISK FACTORS FOR
UNCONTROLLED HYPERTENSION, HOW
IS THE HELT -- HEALTH SYSTEM AD
COMMUNITY ADDRESSING THIS IN
SOME OF THE MOST VULNERABLE
PATIENTS.
SO THERE'S AN OPPORTUNITY TO
INTERSECT THESE PROBLEMS WITH
THE CLINICAL PROBLEM TO ALLOW
THESE SOCIAL DETERMINANTS OF
HEALTH TAKEN--THEY AFFECT THESE
OUTCOMES, PARTICULARLY ADVERSE
OUT COMES WHEN IT AM CANS TO
DIABETES AND HYPERTENSION, IF WE
ARE GOING TO REACH OUT TO THOSE
COMMUNITIES THAT ARE PERHAPS
LAGGING BEHIND, 1 OF THE BEST
INTERVENTIONS IS TO ADDRESS IT
WITH THE THINGS WE ALREADY KNOW
HOW TO WORK AND THEN WORK
THROUGH A COMMUNITY ENGAGED
RESEARCH PARADIGM WITH
IMPLEMENTATION SCIENCE WHETHER
WE CAN TAKE EVIDENCE BASED
RIGOROUS APPROACH TO TESTING,
DIFFERENT STRATEGIES TO OPTIMIZE
THESE HEALTH OUTCOMES.
THIS IS A STUDY THAT IS BEING
PURSUED ON THE CEAL PLATFORM
THAT LEVERAGES THAT EHR
FRAMEWORK, FIRST TO IDENTIFY
THOSE WHO HAVE THOSE COMORBID
SITUATIONS OF UNCONTROLLED
HYPERTENSION AND DIABETES.
AND THEN RECOGNIZE THAT IT'S NOT
ONLY A CALL TO MAYBE INCREASE
THE DOSE OF THEIR DRUGS OR GIVE
THEM MORE PRESCRIPTIONS BUT TO
TAKE A WHOLISTIC VIEW AND
APPRECIATE THAT MAYBE A NUMBER
OF THOSE FACTORS WERE ACTUALLY
SOCIAL AND BEHAVIORIAL, NOT A
MATTER OF PILL TAKING.
AND SO THEY'RE TAKING A
COMMUNITY HEALTH WORKER APPROACH
LEVERAGING THAT ACTIVITY AND AS
A MEANS OF PROMOTING HEALTH
LITERACY, PROMOTING HEALTHY
HABITS AND ALMOST SERVING AS A
NAVIGATOR THROUGH SOCIAL SYSTEMS
TO BE SURE THAT THEY HAVE
WHETHER IT'S TRANSPORTATION OR
FINANCING OR FOOD ASSISTANCE,
RELATED TO THE FOOD INSECURITY,
A REALLY WHOLISTIC VIEW
LEVERAGING COMMUNITY HEALTH
WORKERS IN A WAY OF WRAP AROUND
SOCIAL SUPPORT BUTTRESSING TO
HOPEFULLY ENHANCE BLOOD PRESSURE
AND DIABETES CONTROL AND ENHANCE
OUTCOME.
SO THIS IS BEING TESTED IN A
CLUSTER RANDOMIZED DESIGN HERE,
I GUESS, IT SAYS 26 COMMUNITY
HEALTH CENTERS, ABOUT 3000
PATIENTS AND SO SYSTEMATICALLY
AND RIGOROUSLY TESTING WAYS TO
ADDRESS THE PANDEMIC OR CHRONIC
DISEASE IN THE MOST VULNERABLE
POPULATIONS, LEVERAGING THE SEAL
PLATFORM.
NEXT SLIDE PLEASE.
NEXT SLIDE, PLEASE.
LET ME JUST PIVOT TO ANOTHER
EXAMPLE AND THAT RELATES TO
CHRONIC LUNG DISEASE AND THIS
CLEARLY ILLUSTRATES A CURVE THAT
LITERALLY I SHOWED THAT SLIDE,
PROBABLY MY SECOND DAY AS
DIRECTOR WHERE IT TROUBLED ME SO
THAT YOU KNOW YOU GET ON THIS
CURVE AND IT HAS A SENSE OF
INEXPECTATIONSORRABLE LOST IN
DECLINE IN DEATH AND WE HAVEN'T
DEVELOPED VERY MANY THERAPEUTICS
OVER THE LAST COUPLE DECADES,
THE CHANGES OF THESE CURVES
MODIFYS THE NATURAL HISTORY.
WE HAVE THINGS THAT TREAT
SYMPTOMS AND BUT NOTHING THAT
REALLY MODIFIED THE LUN DISEASE,
THIS IS A CALL TO ACTION.
THIS IS AN AREA WHERE IT NEEDS A
RETHINK IN TERMS OF HOW WE THINK
ABOUT IT CLINICALLY, PROBABLY
NEEDS A RETHINK THAT PROVIDES A
MOLECULAR TAXONOMY OF WHAT'S
GOING ON WITH THESE CURVES, WHAT
IS RESILIENT TO LUNG INJURY,
WHAT OF ANY OF THESE CURVES THAT
CAN BE MODIFIED AND ADJUSTED, WE
KNOW IN CARDIOVASCULAR DISEASE
YOU STOP SMOKING THE CURVES CAN
MODIFY AND CHANGE AND SO I
RADIOLELY NEED TO FIND THESE
DRIVERS, NEXT SLIDE.
AND TOWARD THAT END, HOPEFULLY
LEVERAGING NEW IMAGING
MODALITIES AND PARTICULARLY
IMAGING MODALITIES THAT MAY BE
FURTHER ENHANCED BY THE LAYERING
OF RADIO-OMICs OF AI TO SEE IF
WOO CAN DEVELOP IMAGING
BIOMARKERS THAT ARE MORE
SENSITIVE AND DETECT PRECLINICAL
LUNG DISEASE OR BETTER DEFINE
WHAT LUNG HEALTH IS, AND DEVELOP
THAT RESILIENCE UNDERSTANDING.
SIMILARLY DEVELOPING THOSE
STRATEGIES TO IDENTIFY PATHWAYS
AND SUSCEPTIBILITY IN THIS CASE
TO SUBCLINICAL SORT OF
INTERSTITIAL ABNORMALITIES AND
DISEASE TO FIND THOSE FACTORS
THAT AGAIN MIGHT BE MORE
IMPORTANT EARLY ON.
HERE'S PRECISION MEDICINE OR
HEALTH THAT COULD LEVERAGE NEW
INNOVATIONS AND DATA SCIENCE IN
AI.
SIMILARLY WE SEE NEW
OPPORTUNITIES IN THE INNOVATION
AND AI APPROACHES PARTICULARLY
LEVERAGING MULTIOMICS AND A REAL
MOLECULAR TAXONOMY OF DISEASE
AND HEALTH AND 1 EXAMPLE AGAIN
RELATED TO IDIO PATHIC PULMONARY
FIBROSIS STARTING TO BE PURSUE
AS TO WHETHER WE REQUEST TAKE
PRECLINICAL INFORMATION FROM
ANIMAL MODELS, LAYER IN WHAT WE
KNOW FROM HUMAN SYSTEMS BIOLOGY,
AS WELL AS A DISEASE
PATHOGENESIS IN WAYS TO START TO
IDENTIFY MOLECULAR PATHWAYS,
NETWORKS AND TARGET DISCOVERY,
TARGET VALIDATION THAT THEN CAN
SERVE AS A DRIVER OF NEW
INNOVATIVE DRUGS AND
THERAPEUTICS THAT ARE MORE
TARGETED AND GETS US BEYOND
STEROIDS AND BRONCO-DILATORS IN
A WAY THAT CHANGES NATURAL
HISTORY.
NEXT SLIDE, PLEASE.
INDEED THERE IS THIS 1 EXAMPLE
OF THIS BEING DONE IN THE
PRIVATE SECTOR, SILICO MEDICINE,
I BELIEVE THEY'RE CALLED IN
WHICH THEY'VE TAKEN THESE INPUTS
OF TRYING TO LOOK AT VARIOUS
DATA SETS TO IDENTIFY PATHWAYS
AND NETWORKS OF DISEASE WHETHER
IT'S IN CELLS, TISSUES, VARIOUS
SORTS OF MODELS, ALSO TAKING
ADVANTAGE OF SORT OF HIGH
THROUGH PUT ASSAYS TO FURTHER
CLARIFY TARGETS AND AGAIN,
LEVERAGING DATA SCIENCE AND AI
TOOLS TO MAKE PREDICTIVE MODELS
THROUGH THIS AND IN MANY WAYS
THEY WERE ABLE TO IDENTIFY THIS
PARTICULARLY T& K PATHWAY
TARGET THAT I BELIEVE IS LINKED
UPSTREAM OF TGF BETA AND OTHER
THINGS THAT HAVE BEEN IMPLICATE
INDEED IPF AND DEVELOP A
MOLECULE THAT BEGAN USING AI.
THEY COULD OPTIMIZE AS A
FAVORABLE TARGET AND THEY ARE
INTO PHASE 2 WHERE
PREEMILYINARLY, THEY ARE SEEING
SOME FUNCTIONAL EFFECTS SO IN
MANY WAYS SOME POTENTIAL PROOF
OF PRINCIPLE USING AN AI-DRIVEN
APPROACH OF DRUG DISCOVERY
TARGET AND VALIDATION AND
DEVELOPMENT.
SO WE THINK THIS IS AN EXCITING
AREA WHERE THE NHLBI COMMUNITY
NEEDS TO PARTNER WITH THE
PRIVATE SECTOR TO REALLY DRIVE.
NEXT SLIDE, PLEASE.
AND TOWARD THAT END, WE THINK WE
HAVE A LOT OF THE RESOURCES AND
ELEMENTS FOR AN AI READY SET OF
DATA RESOURCES AND STRATEGIES TO
START TO BEGIN TO DEVELOP
APPROACHES IN DEVELOPING AND
PREEMPTING CHRONIC DISEASES IN
OUR PORTFOLIO, NEXT SLIDE.
AND WE SORT OF END WITH A
FORESHADOWING.
THIS IS STILL EXTREMELY
CONCEPTUAL AND I'M GOING TO BE
DETENDING ON OUR NEW LEADERSHIP
IN DATA SCIENCE AND PRECISION
MEDICINE AS THIS CONTINUES TO
EVOLVE AS A CONCEPT, BUT WE
THINK THERE'S GREAT POTENTIAL
FOR THE NHLBI COMMUNITY TO
REALLY ENGAGE AND INVITE INTO
OUR FIELD REAL DATA SCIENCE AND
AI EXPERTS TO WORK SHOULDER,
SHOULDER AND INTERDISCIPLINARY
TEAM FASHION WHERE YOU HAVE
COMPUTATIONAL BIOLOGISTS AND
CLINICIANS WHO HAVE INDEPTH
UNDERSTANDING OF PHENOTYPE AND
POPULATION SCIENTISTS WHO
UNDERSTAND THESE THINGS AT SCALE
AND ALL GETTING TOGETHER TO
START TO REALLY CHARACTERIZE THE
WHOLE HUMAN SYSTEMS BIOLOGY OF
HEALTH AND IT'S IMPLICATIONS FOR
HEART LUNG AND BLOOD SLEEP
DISORDERS IN WAYS THAT CAN LINK
THE DEEP PHENOTYPING THAT'S
ALREADY IN FOR EXAMPLE, MANY OF
OUR COHORT STUDIES, MANY OF OUR
REGISTRIES, OF VARIOUS SORTS AND
THEN START TO GET THAT IN A
HARMONIZED FORM SUCH THAT WE'RE
ALL SPEAKING THE SAME LANGUAGE
EVEN THOUGH WE OFTEN TALK ABOUT
DIFFERENT ORGANS BUT THEN WE
HAVE WAYS OF INSURING THAT THE
DAILY BASIS THEA COLLECTION IS
ALSO HARMONIZED, AND THEREFORE
MORE MACHINE READABLE AND READY
AND AMINABLE TO LAYERING ON AI
TOOLS, AND APPLICATIONS THAT ARE
DEVELOPED THAT WE HOPE THIS
COMMUNITY ENRICHED BY AI EXPERTS
LOOKING AND WORKING WITH OUR
DATA SETS, WHETHER IT'S IMAGING,
OR OUR MULTIOMICS IN WAYS IN
WHICH HAVEN'T BEEN DEVELOPED
PARTICULARLY USING SOME OF THEIR
NEW TOOLS AND GENERATIVE AI, ET
CETERA AS THAT FIELD MOVES.
AND THEN THESE CAN BE LINKED TO
AI-DRIVEN LUNG AND HEART
PROJECTS MANY OF WHICH WILL BE
DIFFERENT TEST CASES OF HOW
THESE DIFFERENT GROUPS CAN WORK
TOGETHER AND INTERDISCIPLINARY
TEAMS TO UNDERSTAND THESE
MULTILEVEL, MULTIMODAL DATA SETS
THAT ARE ALSO INCLUSIVE OF THE
SOCIAL DETERMINANTS OF HEALTH,
ENVIRONMENT EXPOSURE AS WELL AS
THE IMPACT THEY'RE HAVING ON U
MAN SYSTEMS BIOLOGY.
-- HUMAN SYSTEMS BIOLOGY.
SO WE ENVISION MODULES THAT
MIGHT LINK TO CHRONIC LUNG
DISEASE WHICH WE GAVE AN EXAMPLE
OF MOVING EARLIER IN
INTERSTITIAL LUNG DEC -- DISEAE
AS HAVING A WAY TO HAVE AN
IMPACT ON IPF AND HAVE AN IMPACT
ON IT FOR CHRONIC DISEASE.
WOMEN'S HEALTH WE ALLUDED TO
EARLIER IN CAN WE LOOK AT THE
LIFE SPAN AND RECOGNIZE THAT
PREGNANCY IS A STRESS TEST TO
SOMETHING THAT MAY HAPPEN A
DECADE LATER, IDENTIFYING AND
PRO DICTING OF THAT
TRANSLATIONAL RESEARCH YECTRY,
MODELING OF THAT FACTOR.
THE SAME THING COULD BE SAID FOR
OTHER TRANSITIONS LIKE MACHINE O
PAUSE WHERE TAKING A HUMAN
SYSTEMS BIOLOGY APPROACH, WE CAN
START TO APPRECIATE THE CHANGE
THAT HAPPENS PRE, PERI AND POST
MENOPAUSE AND HOW THE SHIFT
RISKS AND SHIFTS OF DISEASE AND
RESILIENCE.
AND SO, THESE SYSTEMS GIVE US AN
OPPORTUNITY TO DO THAT.
LEVERAGING AS A KEY CENTERPIECE
NHLBI COHORT OF COHORTS, AGAIN
AT SCALE, AND MULTIOMICS WITH
ALL THAT MULTIDIMENSIONAL DATA,
SOCIAL, ENVIRONMENTAL THAT IS
THEN PUT TOGETHER IN WAYS THAT
AGAIN ARE MACHINE READABLE, THAT
CAN HAVE THESE AI APPLICATIONS.
YOU CAN SEE THAT THE SKIN CAN
MOVE TO OTHER PROGRAMS WHETHER
THEY'RE CURRENTLY ENROLLING OR
ENROLLED PREVIOUSLY AND AGAIN,
FITS IN WITH THE MOLECULAR
TAXONOMY OR FOR HEART FAILURE
BEING DONE IN HEART SHARE,
CLEARLY THERE ARE OTHER EXAMPLES
OF SLEEP AND BLOOD THAT WOULD BE
APPLICABLE TO THE SYSTEMS
BIOLOGY COMPUTATIONAL MEDICINE
SORT OF STRATEGY BUILT UPON THE
TOP OF THAT INFRASTRUCTURE OF
DATA OF MULTIOMICS OF AS WELL AS
CLOUD BASED DATA RESOURCE THAT
PROVIDE A CATALYST AND A PLACE
FOR THIS AI TOOL KIT.
WHERE ALL THIS CAN COME
TOGETHER.
SO WE'RE VERY EXCITED ABOUT THE
OPPORTUNITY IT IS AHEAD OF US,
THIS IS I BELIEVE A PLATFORM
THAT WILL BE CRITICAL IF WE ARE
GOING TO PREEMPT CHRONIC
DISEASE.
CERTAINLY DO PRESINGZ
INTERVENTION SO I THINK THIS IS
ALL QUITE TIMELY.
SO NEXT SLIDE, PLEASE.
SO YOU WILL BE HEARING ABOUT THE
CHARGE OF AN AI WORKING GROUP AS
WELL AS OTHER ACTIVITIES THAT
ALIGN WITH THIS ELEMENT AND THIS
VISION AND RETREAT WE HAD LAST
YEAR WHERE DATA SCIENCE AI IS
INTERDISCIPLINARY TEAMS WAS A
MAJOR THEMEATIC TAKE AWAY.
SO WITH THAT I WILL END AND
APPRECIATE THE CIRCLE OF
PARTNERS THAT WILL BE CRITICAL
TO DOING THIS IN A MULTIPRONG,
MULTILEVEL, MULTIMODAL WAY AND
IT WILL TAKE THE ENTIRE
COMMUNITY TO DO IT.
SO THANKS FOR YOUR ATTENTION.
>> THANK YOU DR. GIBBONS DO WE
HAVE ANY OTHER COMMENTS FROM
COUNCIL MEMBERS.
>> AGAIN, THANK YOU.
THAT WAS EXCELLENT.
I REALLY APPRECIATE THE FOCUS
YOU KNOW I THINK HIGHLIGHTING
PARTICULARLY MOST STRUCK ME WAS
PROJECTS THAT INVOLVE THAT
COMMUNITY ENGAGEMENT MECHANISM
AND REALLY EMPHASIZING THE
IMPORTANCE OF YOU KNOW THAT
INPUT AND THAT APPROACH
ADDRESSING SOME OF THESE, OTHER
DETERMINANTS OF HEALTH THAT ARE
CRITICALLY IMPORTANT IN HEALTH
OUTCOMES SO I THINK IT'S REALLY
GREAT TO SEE ALL THE STRONG
WORK.
OVERALL, IN ALL DIRECTIONS BUT
PARTICULARLY THAT FOCUS IS
REALLY GREAT TO SEE THAT
SUSTAINED, YOU KNOW IT'S GOING
TO BE A SUSTAINED FOCUS FOR
INSTITUTE, BUT THANK YOU VERY
MUCH.
I THOUGHT IT WAS WONDERFUL.
>> THANK YOU FOR THE COMMENT.
>> ANY OTHER COMMENTS?
QUESTIONS FROM COUNCIL?
I THOUGHT I SAW A HAND RAISE BUT
DOESN'T LOOK LIKE IT.
OKAY, SO WE'RE AT THE POINT
WHERE WE'RE SCHEDULED TO HAVE A
30 MINUTE LUNCH BREAK AT THIS
POINT IN TIME, AND SO, AT THIS
POINT IN TIME WE WILL RECONVENE
AT 12:45 WITH THE OPEN SESSION.
>> THEY CAN STAY LOGGED IN?
>> THEY CAN STAY LOGGED IN, YES,
YES, THAT MIGHT BE EASIER IF YOU
STAY LOGGED IN.
WE WILL RECONVENE AT 12:45. THANK YOU.
OKAY, WELCOME BACK FROM
LUNCH, EVERYONE.
WE WILL PROCEED WITH THE NEXT
ITEMOT AGENDA WHICH IS OUR
TRIENNIAL INCLUSION REPORT BY
KATHRYN KAVOUNIS, AND THEN WE
WILL OPEN IT UP TO THE COUNCIL
FOR COMMENTS OR QUESTIONS.
THANK YOU, KATIE.
>> ALL RIGHT, THANK YOU VERY
MUCH.
I AM THRILLED TO BE HERE, IT'S
APRIL, BUT IT FEELS LIKE
FEBRUARY, SO, I APPRECIATE BEING
INVITED.
TODAY I AM GOING TO TALK ABOUT
THE TRIENNIAL INCLUSION REPORT,
I WILL TALK A LITTLE BIT ABOUT
THE LAW AND THE POLICIES GOING
INTO THIS REPORTING REQUIREMENT
AND THEN I WILL DIVE INTO OUR
NHLBI DATA.
CAN YOU HEAR ME OKAY?
SO THE TRIENNIAL REPORT IS
MANDATED BY CONGRESS SO EVERY 3
YEARS EACH NIH INSTITUTE AND
CENTER PROVIDES CERTIFICATION OF
OUR COMPLIANCE WITH THE LAWS AND
THE POLICIES OUR REPORT
DESCRIBES OUR PROCEDURES AND HOW
WE COMPLY AS WELL AS THE ACTUAL
DATA AND THIS YEAR'S REPORT WILL
COVER FISCAL YEAR 2022, 23, AND
24.
SO OUR INCLUSION
RESPONSIBILITIES FOR CODIFIED IN
LAW IN THE REVITALIZATION ACT OF
FLEEN 93 AND THIS LAW TALKED
ABOUT WOMEN AND MINORITIES BEING
INCLUDED IN ALL CLINICAL
RESEARCH STUDIES UNLESS THERE
WAS A COMPELLING RATIONAL FOR
EXCLUSION AND THE PURPOSE WAS
REALLY TO MAKE SURE THAT
INVESTIGATORS ARE PROVIDING THE
PARTICIPATES THAT ARE
APPROPRIATE TO THEIR SCIENTIFIC
AIMS AND MAKING SURE THAT THE
RISKS AND BENEFITS WERE EQUALLY
DISTRIBUTED THROUGHOUT OUR
SOCIETY TO LEAD TO GENERALIZABLE
DATA THE LAW ALSO HAS
REQUIREMENTS FOR THAT DATA AND
YOU NOTICE WHEN I DIG INTO THE
DATA YOU WILL SEE THOSE STUDIES,
AND THOSE ARE PROVIDED TO REPORT
ETHNICITY, SEX, AND THE LAW SAYS
WE PROVIDE THAT OUR COUNCILS.
SO AS I MENTIONED, THIS DATA IS
REPORTED BY CONGRESS EVERY 3
YEARS, OUR REPORT DRIEBED OUR
NHLBI PROCEDURES WITH COMPLYING
WITH THE LAWS AND POLICIES IN
GUIDANCE AND WILL SUMMARIZE THE
ACTUAL DATA AND AGAIN, THE
PURPOSE IS TO CERT NIGH OUR
COMPLIANCE AND NOTICE OUR
COUNCIL, BOTH OF THESE GROUPS
ARE FOCUSED ON HAVING
INVESTIGATORS ENROLL THE RIGHT
PARTICIPANTS FOR THEIR STUDIES
BASED ON THE SCIENTIFIC AIMS AND
IT REQUIRES THAT INVESTIGATORS
IN THE APPLICATIONS DESCRIBE
THEIR PLANS AND JUSTIFY ANY
EXCLUSIONS AND AGAIN, PHASE 3
CLINICAL TRIALS ARE ALSO
REQUIRED TO PERFORM VALID
ANALYSIS BY SEX, RACE AND GENDER
AND ETHNICITY AND REPORT THOSE
IN CLINICAL TRIALS .GOV.
IN 2019 I WANT TO MENTION THERE
WERE CHANGES IN THE INCLUSION OF
LIFE SPAN POLICY, INITIALLY IT
WAS CHILDREN AND IT WAS
BROADENED TO ALSO INCLUDE A
FOCUS ON OLDER ADULTS AND THIS
HAS AN IMPACT ON OUR AGE DATA
THEY WILL BE PRESENTING LATER
BECAUSE IT LAUNCHED A NEW
ENVIRONMENT FOR INVESTIGATORS TO
REPORT AGE AT ENROLLMENT.
SO WHAT ARE OUR TERMS, THERE'S
REVIEW AND PROGRAMS AND GRANTS
MANAGEMENT AND PAID AND ARE
THOSE JUSTIFIED FOR THE
SCIENTIFIC AIMS OF THE STUDY AND
WE WANT TO MAKE SURE THE
PROPOSED PORTION OF THE STUDY
PARTICIPANTS ARE APPROPRIATE FOR
THE DISEASE BEING STUDIED AND IF
THEY ARE TO BE GENERALIZED
ACROSS A BROADER POPULATION THEN
WE START LOOKING AT THE
INFORMATION IN THE U.S. CENSUS
WHICH THE LATEST VERSION SHOWED
51% WOMEN AND 38% NONWHITE
INDIVIDUALS AND NOT ONLY DO WE
WANT TO MAKE SURE THAT
INVESTIGATORS ARE PROPOSING
APPROPRIATE PLANS BUT WE ALSO
WANT TO HOLD THEM ACCOUNTABLE SO
WHEN PROGRESS IS REVIEWED WE
WANT TO MAKE SURE THEY ARE
MEETING THEIR TARGETS.
SO AS I MENTIONED OUR REPORT
WILL BE POSTED TO CONGRESS AND
POSTED ON THE PUBLIC WEBSITE.
THERE'S THE LINK WHERE THESE
DATA ARE POSTED AND THE DATA ARE
PRESENTED BOTH IN TERMS OF NIH
AGGREGATE DATA BUT ALSO BY EACH
INSTITUTE OR CENTER.
THE DAILY BASIS THEA I'M
COVERING TODAY WILL COVER GRANTS
AND CONTRACTS WITH HUMAN
SUBJECTS AND EXCLUDES ANALYSIS
OF EXISTING DATA SETS.
SO TODAY I WILL TALK ABOUT
ENROLLMENT.
SO OUR FIRST SET OF GRAPHS AND
TABLES TALK ABOUT THE OVERALL
ENROLLMENT, IT'S BROKEN DOWN FOR
22, 23, AND 24.
YOU WILL SEE IN 22, WE'RE
REPORTING 490 -- OVER 490,000
PARTICIPANTS AND THEN A BIG JUMP
IN 2023, AND 2024 SO THE LOWER
NUMBERS IN 22 ARE IN LINE WITH
THE LOWER COVID FIGURES, WE DID
HAVE A DROP AND THEN IN 23 AND
24 WE BUMPED BACK UP TO MORE
NORMAL PRECOVID NUMBERS BUT IF
WE TAKE A CLOSER LOOK AT THE
DATA BROKEN DOWN BY THE GREEN
SECTION OF THE GRAPH, THE BLUE
PARTICIPANTS ARE U.S. ENROLLMENT
VERSUS THE ORANGE WHICH ARE
FOREIGN PARTICIPANTS THAT CHANGE
IN ENROLLMENT IS PRETTY MUCH
MADE UP BY NEW FOREIGN
ENROLLMENT.
SO WHEN WE DUG A LITTLE DEEPER
INTO THE DATA WE REALIZE THAT
OUR PARTICIPANTS IN 2023, THAT
INCREASE IN FOREIGN PARTICIPANTS
WAS REALLY ACCOUNTED FOR BY
THROUGH NEW STUDIES ACROSS
NIGERIA AND UGANDA, SO AS I GO
THROUGH THE REST OF THE CHARTS,
I WILL TAKE SOME TIME TO CALL
OUT KIND OF HOW THESE DATA
INFLUENCE OUR OVERALL NUMBERS
AND WE'RE REQUIRED TO ALSO DIG
DEEPER INTO OUR PHASE 3 CLINICAL
TRIALS BASED ON ADDITIONAL
REQUIREMENTS FOR THOSE STUDIES
AND FOR THESE DATA, ACROSS 2022,
AND 2023, WE WERE AT OVER 70,000
PARTICIPANTS IN THESE PHASE 3
TRIALS AND THEN WITH A LARGE
DROP IN 2024 DOWN TO JUST OVER
26,000 AND THIS WAS REALLY
ACCOUNTED FOR BY THE COMPLETION
OF THE WISH TRIAL, AND THIS WAS
AMONG PARTICIPANTS IN THE
WOMEN'S HELT INITIATIVE, SO IT
WAS OVER 49,000 WOMEN IN THIS
PHASE 3 TRIAL SO AGAIN AS I MOVE
THROUGH THE OTHER GRAPHS WE WILL
SEE HOW THIS WHISH TRIAL
IMPACTED THE DEMOGRAPHIC AND
OTHER SLIDES.
SO ENROLLMENT BY SEX AND THIS S
AGAIN ALL HUMAN RESEARCH, ACROSS
THE YEARS WAS PRETTY CONSISTENT,
THE ORANGE SECTION OF THE PIE
HERE IS FEMALE ENROLLMENT WITH
THE BLUE AS MALE AND 3% IN 2022
THAT GRAY BAR IS UNKNOWN.
SO AGAIN, WE HAVE 55% IN 2022,
58% WOMEN IN 2023, AND 54% IN
2024 AND AGAIN, THIS IS MY THIRD
TRIENNIAL REPORT, SO ACROSS THE
YEARS, THIS IS A FAIRLY
CONSISTENT PERCENTAGE FOR
ENROLLMENT OF WOMEN.
WHEN WE DIG DOWN INTO THE PHASE
3 TRIALS, WE SEE THAT THIS LARGE
WISH TRIAL, AGAIN REALLY SKEWS
THE DATA IN 2022 AND 2023.
SO IT LOOKS LIKE WE HAVE 81%
ENROLLMENT OF WOMEN IN 2022 AND
2023, BUT IF WE LOOKED AT THOSE
SAME YEARS WITHOUT THE WISH
TRIAL, WE WOULD BE AT 48% WOMEN
AND 41% ACROSS 2022 AND 2023.
AND THAT'S SIMILAR TO 2024 AFTER
THE WISH STUDY WAS COMPLETED
WHERE WE'RE 844% ENROLLMENT OF
WOMEN AND WHEN I LOOK BACK AT
THE TRIENNIAL REPORTS THOSE
ENROLLMENT RANGED FOR WOMEN IN
PHASE 3 TRIALS FROM 48% TO 42%.
SO THIS IS STILL THE 2024
NUMBERS ARE STILL PRETTY SIMILAR
AND THERE'S ROOM FOR IMPROVEMENT
IN OUR ROLE OF WOMEN IN PHASE 3
TRIALS.
THE NEXT SET OF SLIDES ARE BUSY,
I KNOW BUT THEY BREAK DOWN THE
ENROLLMENT OF OUR PARTICIPANTS
BY SELF-REPORTED RACE
CATEGORIES.
SO THE FIRST COLUMN IS 2022,
FOLLOWED BY 2023 AND 2024, AND
THE STOP SLICE THIS DARK PURPLE
COLOR ARE UNKNOWN OR NOT
REPORTED EMPLOY SO THE 7.9% AND
7.2% AND 7.5% ACROSS THE YEARS
ARE WHERE THE INVESTIGATORS
DIDN'T REPORT OR DIDN'T GET TO
COLLECT THE DATA.
THE NEXT SLICE IS THOSE WHO
REPORTED MORE THAN 1 RACE.
THE LARGER BLUE ARE PARTICIPANT
WHO IS CONSIDER THEMSELVES TO BE
WHITE AND THE FIGURES DECREASED
A LITTLE BIT AND I WILL TALK
MORE ABOUT THAT IN JUST A
SECOND.
THE NEXT SECTION IT'S HARD TO
SEE BUT IT'S NATIVE HAWAIIAN AND
PACIFIC ISLANDERS, AND IT
RAINCHLED FROM .2% TO .1% TO .2%
AGAIN IN 2024 AND THIS IS LOWER
THAN THE U.S. CENSUS RATE.
THE NEXT BIGGER SECTION IN GRAY
ARE PARTICIPANTS WHO REPORTED AS
BLACK OR AFRICAN AMERICAN.
IN 2022, WE'RE AT 23%, UP TO 44%
IN 2023, AND AT 41.8% IN 2024.
AND THEN THE NEXT SECTION ARE
ASIAN PARTIC PLAN TO ANALYZE BY
AGES IN THE PURPLE COLOR
FOLLOWED BY NATIVE AMERICAN
INDIAN IN ALASKA NATIVE.
SO THE INCREASE THAT WE NOTICED
IN 2023, AND 2024 IN THE BLACK
ARE AFRICAN AMERICAN CATEGORY
WAS ALSO INFLUENCED AS A
MENTIONED EARLIER ABOUT THE 3
LARGE STUDIES IN UGANDA AND
NIGERIA THAT WERE LAUNCHED IN
2023.
SO WHEN WE DIG A LITTLE DEEPER
AND LOOK ONLY AT DOMESTIC
ENROLLMENT, THE PERCENTAGE OF
AFRICAN AMERICAN PARTICIPANTS
DOES DECREASE, SO IN 22 WE'RE
LOOKING AT 16.4%, 2023, 17.5 AND
2024, 18.2.
BUT THIS IS HIGHER THAN THE U.S.
CENSUS REPORTED AS 14%.
AND THIS IS AN IMPROVEMENT OVER
THE PREVIOUS TRIENNIAL REPORTS.
NEXT LOOKING AT PHASE 3 CLINICL
TRIALS, THE DATA SHOWS 14.1%, IN
2022, AND 18.4% IN 2023, AND A
JUMP TO 47.3% IN 2024.
SO WHEN WE DUG DEEPER INTO THE
DATA WE REALIZED WE ENROLLED THE
SAME NUMBER OF AFRICAN AMERICAN
PARTICIPANTS ACROSS THE YEARS
BUT THE PERCENTAGE REALLY YUSM
INDEED 2024 WHEN THE WHISH TRIAL
COMPLETED BECAUSE AGAIN IT WAS
49 FEMALE PARTICIPANTS AND THEY
WERE 41,000 OF THOSE WERE WHITE.
SO WHEN THAT STUDY COMPLETED OUR
OTHER RACIAL ASK ETHNIC
CATEGORIES REALLY JUMPED UP IN
THE PERCENTAGES.
I LOOKED AT JUST THE DOMESTIC
ENROLLMENT AND AGAIN, WE SAW THE
SAME PATTERN, SO I REALLY THINK
THIS WAS ANART AN ARTIFACT OF E
WHISH STUDY COMPLETED.
THE NEXT STUDY WAS BY THE
PARTICIPANTS FOR HISPANIC LATINO
OR NONHISPANIC OR LATINO, AND
WE'RE ABOUT 12% IN 2022, 23% IN
20 -- SORRY 9% IN 2023, AND 10%
IN 2024.
AND THIS IS SIGNIFICANTLY LOWER
THANLET U.S. CENSUS WHICH IS
REPORTING 19% OF HISPANIC OR
LATINO CITIZEN.
SO WE WOULD LIKE TO YOU KNOW
FOCUS ON THIS AS AN AREA OF
IMPROVEMENT FOR THE FUTURE.
WHEN WE DIG DEEPER AND LOOK AT
PHASE 3 CLINICAL TRIALS, WE SEE
SIMILAR UNDERREPRESENTATION WITH
11% IN 2022, 7% IN 2023, AND
THEN 6% IN 2024 BUT PART OF THAT
IS AN ARTIFACT, 1 LARGE STUDY
THAT DIDN'T REPORT.
SO WE HAD A MUCH LARGER UNKNOWN
OR NOT REPORTED.
WHEN I REMOVED THAT STUDY, IT
BROUGHT OUR HISPANIC OR LATINO
PERCENTAGE UP TO 7% BUT STILL
THIS IS AN AREA WHERE WE SHOULD
FOCUS ON THE FUTURE.
AND THE LAST BIT OF DATA THAT WE
HAVE IS THE NEW REPORTING BY AGE
CATEGORIES.
SO AS I MENTIONED IN 2019,
INVESTIGATORS ARE REQUIRED TO
START REPORTING BY AGE AT
ENROLLMENT AND I GROUPED THE
DATA HERE BY COLOR, THE FIRST
BLOCK OF BARS IN THE BLUE HERE
ARE PARTICIPANTS LESS THAN 18.
AND WE WERE AT ABOUT 12% OF OUR
ENROLLMENT, THE RED BARS ARE
18-64 YEAR-OLDS WHICH IS ABOUT
57% OF OUR ENROLLMENT AND THEN
26% ARE THE GREEN BARS, 65 AND
OLDER AND THIS WAS 1 CATEGORY
WHERE WE WERE DIFFERENT THAN THE
NIH LEVEL, WE ARE -- OUR DATA
SKEWED OLDER OBVIOUSLY FROM OUR
FOCUS ON CHRONIC DISEASES BUT
ANOTHER DIFFERENCE IN THE NHLBI
DATA THAT I WANTED TO CALL OUT
IS THIS LAST GRAY BAR, THE
UNKNOWN OR NOT REPORTED SO NHLBI
IS REPORTING UNKNOWN%, UNKNOWN
OR NOT KNOWN FOR THESE AGE
CATEGORIES VERSUS THE NIH WIDE
LEVEL WHICH IS 25%.
SO NHLBI DID A TERRIFIC JOB SO
KUDO TO OUR STAFF AND
INVESTIGATORS FOR GETTING THIS
NEW DATA IN.
IT'S A COMPLICATED PROCESS WHERE
INVESTIGATOR VS TO UPLOAD A
SPREADSHEET AND IT HAS TO BE,
YOU KNOW PERSNICKETY SYSTEM TO
UPLOAD THAT DATA SO I AM VERY
PROUD OF OUR STAFF AND
INVESTIGATORS FOR GOING ABOVE
AND BEYOND AND GET THANKSGIVING
DATA IN.
WITH THE NHLBI POLICIES AND OUR
NEXT STEPS WILL REALLY BE TO
CONTINUE TO DIG INTO THE DATA.
I'M LOOKING FORWARD TO LOOKING
INTO DIVISION LEVEL AND
PORTFOLIO LEVEL DATA TO HELP US
UNDERSTAND NOT ONLY WHERE WE
NEED TO IMPROVE BUT ALSO
IDENTIFY AREAS WHERE WE'RE BEING
SUCCESSFUL AND HELPING TO
IDENTIFY LESSONS LEARNED AND
BEST PRACTICES SO WE CAN
CONTINUE TO SUPPORT OUR
INVESTIGATOR AND STAFF WITH MORE
GUIDANCE AND RESOURCES.
WE DON'T WANT INVESTIGATORS TO
HAVE TO REINVENT THE WHEEL EVERY
TIME THEY'RE HAVING INCLUSION
ISSUES OR LAUNCHING NEW STUDIES
SO I THINK THAT WILL PROBABLY BE
THE FOCUS OF OUR NEXT STEPS.
AND BEFORE I SIGN OFF I WANT TO
RECOGNIZE MY OFFICE OF RESEARCH
CLINICAL STAFF FOR DOING AN
AMAZING JOB, THEY REVIEWED
THOUSANDS OF STUDY RECORDS AND
DID A LOT OF DATA CLEANING SO I
APPRECIATE ALL THOSE EFFORTS.
SO THANK YOU.
I'M HAPPY TO ANSWER ANY
QUESTIONS.
>> THANK YOU.
IF WE COULD SEE THE PANEL AND
THE COUNCIL MEMBERS AND I SEE 1
HAND RAISED, DOCTOR IN.
>> THANK YOU THAT WAS AN
EXCELLENT PRESENTATION, YOU
MENTIONED 2 STUDIES IN UGANDA
AND NIGERIA THAT BUMPED UP THE
ENROLLMENT NUMBERS I THINK IN 2
CONSECUTIVE YEARS, COULD YOU
GIVE US A LITTLE BIT MORE ABOUT
THOSE STUDIES, WHAT STUDIES WERE
THOSE?
>> YOU KNOW I DON'T HAVE VERY
MANY DETAILS ON THOSE, I KNOW
THAT THEY WERE IMPLEMENTATION
SCIENCE STUDIES WHERE THEY WERE
LOOKING, I KNOW 1 OF THEM WAS
LOOKING AT SOME NEW
IMPLEMENTATION PROJECTS FOR
BLOOD PRESSURE, AND I CAN'T --
OFF THE TOP OF MY HEAD I CAN'T
REMEMBER THE DETAILS BUT I KNOW
THEY WERE REALLY EXCITING
IMPLEMENTATION SCIENCE STUDIES.
>> OKAY, THANK YOU.
>> I AM HAPPY TO PROVIDE THAT
INFORMATION.
>> I WOULD APPRECIATE THAT IF
YOU CAN.
>> SURE.
>> THANKS, KATIE.
>> DR., THIS IS GEORGE, I WANT
TO CONFIRM THAT THAT IS
ACCURATE, THOSE THAT WERE IS
ITED FROM CENTER AND I CAN SEND
A BRIEF SYNOPSIS TO YOU BOTH
FOLLOWING THIS MEETING.
>> THANKS NTHANK YOU.
>> DR. REDLINE.
>> THANK YOU VERY MUCH THAT WAS
REALLY HELPFUL AND SO CLEAR, AND
I WANT TO PERSONALLY THANK YOUR
STAFF.
I'M 1 OF THE HUNDREDS OF
INVESTIGATOR WHO IS STRUGGLED
WITH SOME OF THOSE SPREADSHEETS
AND THIS WAS FANTASTIC IN
RESOLVING PROBLEMS, I REMEMBER
ONCE OR TWICE, SO THANKS FOR
THAT.
SO I HAD 1 COMMENT AND THEN 2
QUESTIONS.
ONE COMMENT IS, I KNOW THIS IS
ALL PRESENTED WITHIN THE
FRAMEWORK OF WHAT IS FEDERAL
ENVIRONMENTS BUT I WOULD JUST
ALSO NOTE THAT IN ADDITION TO
TRYING TO EMULATE OR A PARALLEL
THE POPULATION DISTRIBUTIONS, WE
ALSO HAVE A SCIENTIFIC IM
PERRATIVE TO BE ABLE TO DO
MEANINGFUL SUBGROUP ANALYSIS.
SO AGAIN, YOU KNOW AND -- AND SO
WE OFTEN DO NEED TO OVERENROLL,
YOU KNOW GROUPS WHERE THERE'S
SPECIAL INTEREST, BECAUSE OF
THEIR PROPENSITY FOR DISEASE
JUST SO THAT EXPLORE POTENTIAL
SUBGROUP ANALYSIS AND I HOPE
SOMEHOW THAT GETS BAKED INTO HOW
WE THINK ABOUT SOME THESE
DISTRIBUTIONS BECAUSE IT'S MORE
THAN JUST BEING REPRESENTATIVE
WHICH I KNOW EVERYONE RECOGNIZES
I JUST FEEL I WANTED TO SAY THAT
BUT I GUESS I HAD 2 QUESTIONS.
ONE WAS SIMPLY THERE ARE MANY,
MANY INCREDIBLE COHORTS OUT
THERE THAT DIDN'T GET ENROLLED
IN MULTIPLE ANCILLARY STUDIES
THAT THEN MAY GET REPORTED AS
BEING ENROLLED IN ANN SILLARY
STUDY.
DO THEY APPEAR AS DUPLICATES IN
YOUR ANALYSIS OR ARE THEY ALL --
DO YOU TAKE CARE OF THAT?
>> NO, THAT'S A GREAT QUESTION.
AND IN THESE ANALYSIS, WE'RE
ONLY RECORDING PROSPECTIVE
ENROLLMENT SO IN AN ANCILLARY
STUDY WHERE THEY'RE CONDUCTING
STUDIES ON EXISTING SPECIMENS OR
DATA IN THE SYSTEM THOSE HAVE A
LITTLE CHECK MARK AND THOSE ARE
CONSIDERED EXISTING DATA SETS.
SO WE DO ONLY WANT TO COUNT EACH
PARTICIPANT ONCE UNLESS THERE'S
NEW ENROLLMENT OR NEW CONSENTING
AND THINGS LIKE THAT.
>> OKAY, THERE IS THIS SUBTLY
BECAUSE SOME COHORTS OBVIOUSLY
REENROLL PARTICIPANTS SO WE'RE
ESSENTIALLY DIPPING SEVERAL
TIMES IN THE SAME GROUPS AND IT
MIGHT BE WORTH THINKING ABOUT,
YOU KNOW NEW PEOPLE VERSUS THE
SAME PEOPLE.
>> GREAT 1.
>> AND THEN MY LAST SORT OF
QUESTION, I MEAN I WAS REALLY
SORT OF DISAPPOINTED ABOUT THE
RELATIVELY LOW ISOTOPE PANIC
ENROLLMENT, I WAS JUST WONDERING
IF YOU HAVE ANY SENSE WHETHER
THAT'S ATTRIBUTABLE TO SPANISH
LANGUAGE BARRIERS THAT IMPACT
ENROLLMENT OR YOU KNOW OTHER
CULTURAL, YOU KNOW OTHER ISSUES?
>> YEAH, DEFINITELY.
I THINK YOU KNOW EVERY STUDY IS
DIFFERENT AND HAS ITS OWN ISSUES
BUT I THINK, YOU KNOW WE'RE
HEARING A LOT ABOUT YOU KNOW
SPANISH LANGUAGE, CHALLENGES,
BUT ALSO SOME KIND OF MISTRUST
OR, YOU KNOW QUESTIONABLE
SCIENCE, PEOPLE WHO ARE
DISTRUSTING SCIENCE THESE DAYS
OR NERVOUS TO ENROLL IN STUDIES.
SO YOU KNOW I THINK WE WILL HAVE
CHALLENGES AHEAD OF US AT
MITIGATING THEZ THOSE ISSUES FOR
SURE.
>> THANK YOU VERY MUCH.
>> DR.?
>> THANK YOU AND FOLLOWING UP ON
THE EXCELLENT POINT ABOUT LATINA
ENROLLMENT BECAUSE I DO SHARE
THAT CONCERN, I THINK YOU HIT IT
ON THE NAIL ABOUT LANGUAGE, YOU
KNOW JOB, SOME RELUCTANCE TO
PARTICIPATE IN RESEARCH BUT ALSO
IF YOU LOOK AT AGE ADJUSTMENT
BECAUSE YOU KNOW, --
>> WE HAVEN'T YET.
>> -- BUT ADJUSTED BY AGE, YOU
WOULD SEE A SLIGHTLY BETTER
NUMBER, STILL NEEDS ATTENTION
BUT YOU KNOW THAT'S 1 THING TO
CONSIDER.
THE OTHERS DO YOU KNOW AND I
THINK YOU HINTED AT IT, HOW THIS
DATA COMPARES TO OTHER ICs AT
THE NIH?
>> YEAH, WE HAVEN'T LOOKED AT
TOO MUCH COMPARING, DRILLING
DOWN TO NHLBI VERSUS THE OTHER
ICs BUT AT THE NIH LEVEL,
WE'RE PRETTY CONSISTENT.
WE'RE DOING A LITTLE BETTER THAN
NIH WIDE WITH OUR ENROLLMENT OF
WOMEN ESPECIALLY IN PHASE 3
KRINICAL TRIALS WHICH WE NEED TO
IMPROVE, SO OBVIOUS LOW, ALL OF
NIH NEEDS TO IMPROVE.
AND THEN IN OUR RACIAL AND
ETHNIC ENROLLMENT, WE ARE PRETTY
ON PARWITH MOST OF THE NIH, SO I
THINK AGAIN, WE'RE IMPROVING AND
LEADING THE PATH IN ENROLLMENT
OF WOMAN AND JUST ABOUT THE SAME
AS OTHER ICs IN OUR RACIAL AND
ETHNIC ENROLLMENT.
THERE'S ALWAYS ROOM FOR
IMPROVEMENT.
>> THANK YOU.
DR.?
>> THANK YOU SO MUCH FOR THE
WONDERFUL REPORT.
IT'S VERY GOOD TO HEAR THAT THE
SEX BASED ENROLLMENT IS EQUAL
AND STRONG ESPECIALLY GIVEN THE
RECOMMENDATIONS PUT OUT BY A
NUMBER OF CARDIOLOGY JOURNAL
EDITORS TO INSURE THAT WHERE
POSSIBLE RESULTS ARE PRESENTED
STRATIFIED BY SEX SO THAT WE CAN
UNDERSTAND WHETHER OR NOT
THERAPIES ARE EQUALLY EFFECTIVE.
A DOMAIN THEY DON'T SEE OFTEN
COVERED AND I UNDERSTAND THAT IT
WAS NEVER PART OF A
CONGRESSIONAL DIRECTIVE, IS 1
AROUND STUDYING INDIVIDUALS WITH
DISABILITY BOTH INTELLECTUAL
DISABILITIES AS WELL AS PHYSICAL
DISABILITIES AND IT'S A LARGE
PROPORTION OF OUR POPULATION,
MANY OF WHOM ARE SEDENTARY AND
SO IN THIS FOR A NUMBER OF THE
DIFFERENT CHRONIC DISEASES THAT
ARE RELEVANT TO THE
CARDIOVASCULAR BRANCH AND THE
LUNG BRANCH AND I'M WONDERING
WHETHER OR NOT THERE'S ANY SPACE
OR ROOM FOR THINKING ABOUT
EMPHASIZING INCLUSION FOR
INDIVIDUALS WITH DISABILITIES?
>> I AGREE 100%.
ORIGINALLY WE DID HAVE
INITIATIVES WE WERE GOING TO
HIGHLIGHT DUE TO TIME WE HAD TO
CUT THOSE OFF BUT WE DO HAVE
SOME CONGENITAL HEART DISEASE
AND DOWNS SYNDROME INITIATIVES
WE WERE THINKING ABOUT MOVING
FORWARD SO WE'RE HOPING TO BE
ABLE TO CONTINUE THOSE TYPES OF
PROJECTS AND I KNOW NIH-WIDE
THERE HAVE BEEN SOME WORKSHOPS
AND SOME HOPEFULLY ADDITIONAL
RESOURCES FOCUSED ON INCLUSION
OF PARTICIPANTS WITH
DISABILITIES AND I THINK, YOU
KNOW SIMILAR TO OUR PAST OF
EXCLUDING CHILDREN OR PREGNANT
WOMEN FROM CLINICAL RESEARCH,
WHAT HAPPENS IS YOU KNOW THE
PLAN, AND THE THINKING IS, WE
WILL PROTECT THESE PARTICIPANTS
FROM RISK BUT THEN WE ALSO END
UP EXCLUDING THEM FROM THE
BENEFITS.
SO I AGREE WHOLE HEARTEDLY THAT
YOU KNOW THIS FOCUS ON
PARTICIPANTS WITH DISABILITIES
SHOULD BE ENHANCED.
THANK YOU FOR THAT.
>> THANKS.
>> ANY OTHER COMMENTS FOR
KATHRYN?
OKAY.
THANK YOU.
>> TERRIFIC.
THANK YOU.
>> OKAY, SO WE WILL MOVE ON WITH
OUR AGENDA OUR NEXT SPEAKER IS
VIRTUAL.
SO WE HAVE DR. SEAN MOONEY,
DIRECTOR OF CENTER FOR
INFORMATION TECHNOLOGY AT NIH,
HE OVERSEES SUPER COMPUTER,
ADVANCED NETWORKING CLOUD BASE
SERVICES, COLLABORATION AND
TOOLS TO SUPPORT RESEARCH.
HEAISE -- HE WAS PRIOR TO
JOINING NIH HE WAS PROFESSOR AT
UNIVERSITY OF WASHINGTON WHERE
HE HAD VARIOUS ROLES INCLUDING
AS CHIEF SERVICE INFORMATION
OFFICER AND INFOMARTICS HE HOLDS
A Ph.D. IN PHARMACEUTICAL
CHEMISTRY FROM UCSF, AND HE HAS
AN UNDERGRADUATE DEGREE FROM THE
UNIVERSITY OF WISCONSIN AND
MEMBER OF THE AMERICAN COLLEGE
FOR MEDICAL INFORMATICS SO WE
WILL WELCOME DR. MOONEY WHO WILL
SPEAK TO US ABOUT ENABLING
ACCESS AND INNOVATION WITH
ADVANCED TECHNOLOGY.
>> AWESOME, CAN YOU HEAR ME
OKAY.
>> WE CAN.
>> I WILL SHARE MY SCREEN, IS
THAT ALL RIGHT?
>> YES, THAT'S FINE.
>> OKAY, GREAT.
I WILL SHARE MY SCREEN.
LET ME KNOW IF YOU CAN SEE IT
OKAY?
>> YES, WE SEE IT.
>> OKAY, EXCELLENT.
SO THANK YOU VERY MUCH FOR THE
OPPORTUNITY TO PRESENT TODAY.
FIRST OF ALL I'M INCREDIBLY
SORRY THAT I'M NOT THERE IN
PERSON, WITH THE RESCHEDULE IT
DIDN'T FIT WITH MY SCHEDULE TO
BE THERE BUT I'M VERY HONORED TO
BE PRESENTING TO YOU TODAY.
I AM RELATIVELY NEW TO THE NIH,
AS YOU HEARD EARLIER, I'VE BEEN
HERE FOR ABOUT A YEAR AND MAYBE
A MONTH OR SO, SO I'M STILL
REALLY GETTING MY FEET WET.
WHAT I WILL TALK TO YOU ABOUT
TODAY IS COMPUTING, HOW WE DO
COMPUTING AT THE NIH, WHAT WE
ARE THINKING ABOUT, WHAT WE DO
IN TERMS OF COMPUTING AND GIVE
YOU SOME SENSE OF WHAT OUR
STRATEGY IS MOVING FORWARD.
COMPUTERS AND THE ANALYSIS OF
DATA IN AI ARE EVERYTHING TODAY.
I THINK THAT WE SPEND 90% OF OUR
TIME IN FRONT OF COMPUTERS, IT'S
ABSOLUTELY CRAZY HOW MUCH EFFORT
OF SCIENCE ACTUALLY NOW IS
SKITING IN FRONT OF A COMPUTER.
SO OUR COMPUTATIONAL
INFRASTRUCTURE TO SUPPORT BOTH
THE ADMINISTRATION OF THE NIH,
BUT ALSO THE CYBER
INFRASTRUCTURE THAT SUPPORTS OUR
BIOMEDICAL RESEARCH
INFRASTRUCTURE NATIONALLY IS
INCREDIBLE LIE IMPORTANT AND I
THINK YOU KNOW ALL OF OUR
INTEREST IN DATA SHARING, OUR
INTEREST IN DEVELOPING STANDARDS
TO ENABLE INTEROPERABILITY OF
DATA, TO IMPROVE STATISTICAL
POWER FROM THE DATA SETS THAT WE
COLLECT WHETHER IT BE RESEARCH
DATA SETS OR SECONDARY USE DATA
SETS LIKE FOR EXAMPLE LIKE
CLAIMS DATA OR REAL WORLD
CLINICAL DATA, THINGS LIKE THAT
ALL COME DOWN TO OUR ABILITY TO
PUT IN PLACE YOU KNOW
COMPUTATIONAL INFRASTRUCTURE OR
COMPUTER BASED TOOLS THAT
SUPPORT WHAT WE DO AND SO FOR
THE NEXT FEW MINUTES OR SO I
WILL TELL YOU WHERE WE'RE AT.
WE STILL HAVE A LONG WAY TO GO
AND WE'RE NOT THERE YET AND I
THINK WE WON'T EVER BE THERE, I
THINK WE WILL ALWAYS BE MARCHING
TOWARD WHERE WE WANT TO GO.
SO WHAT WE WILL START WITH IS
COMPUTING AT THE NIH, HOW WE'RE
SUPPORTED AND STRUCTURED AND
ORGANIZED AND WHAT -- AND THEN
TALK A LITTLE BIT ABOUT OUR
SUCCESS STORIES AND THAT IS WHAT
WE DO AND HAVE BEEN SUCCESSFUL
WITH, WE'RE CLOUD FORWARD
ORGANIZATION AND HOW WE'RE
SUPPORTING, AND I'LL TALK A
LITTLE BIT ABOUT AI, ALWAYS AN
IMPORTANT AND YOU KNOW VERY
EXCITING TOPIC AND THEN I'LL
TALK ABOUT CYBER INFRASTRUCTURE
AND WHAT WE'RE THINKING ABOUT
FOR THE FUTURE AND WHAT OUR
GUIDES PRINCIPLES ARE OF HOW WE
APPROACH THAT AND HOPEFULLY WE
WILL GIVE YOU SOME SENSE OF THE
FUTURE.
AND THEN WE CAN DO A DISCUSSION
THE WAY I THINK ABOUT ALL THIS
IN TERMS OF TECHNOLOGY AT THE
NIH, AND WE HAVE INCREDIBLE IT
TEAM THAT SUPPORTS BROADLY NIH
COMPUTING ACTIVITIES, WE DON'T
KNOW EXACTLY HOW MUCH THE BUDGET
IS ACROSS ALL ICs FOR IT BUT
YOU CAN FIGURE IT'S BETWEEN 1.5
AND 2 BILLION DOLLARS A YEAR AND
THAT SUPPORTS ALL OF THE THINGS
YOU MIGHT IMAGINE THAT SUPPORT
THAT SUPPORT COMPUTING FROM KIND
OF THE BORING NONSCIENTIFIC
THINGS LIKE THE NIH NETWORK ALL
THE WAY THROUGH TO THE KIND OF
DATA PLATFORMS AND INFORMATICS
THAT SUPPORT SCIENCE.
ABOVE THE PEOPLE IS OUR
ENTERPRISE INFRASTRUCTURE TO
PROTECT OURSELVES FROM OUTSIDE
THREATS BUT ALSO THE
INFRASTRUCTURE THAT SUPPORTS
EVERYWHERE FROM THE TEAMS
MEETING TO THE NETWORK IN THE
ROOM THAT YOU'RE SITTING IN ALL
THE WAY THROUGH TO YOU KNOW ALL
OF THE KINDS OF THINGS THAT WE
HAVE TO DO TO SUPPORT OUR
ENTERPRISE.
ABOVE THAT WE HAVE CLOUD
SERVICES AND WHAT I CALL MODULAR
CYBER INFRASTRUCTURE ARE, I WILL
TALK ABOUT MORE OF THAT IN A BIT
BUT WE LIKE TO THINK ABOUT THESE
TOOLS THAT UTILIZES BY THE
RESEARCH COMMUNITY AND THE ICs
LIKE LEGO BRICKS, THEY'RE
MODULAR, OPEN, EASY TO USE AND
THEY CAN BE PUT TOGETHER IN A
WAY THAT A DATA SCIENTIST OR YOU
KNOW INFORMATION TECHNOLOGY
SPECIALIST CAN LEVERAGE AND MAKE
USEFUL ABOVE THAT WE HAVE DATA
PLATFORMS AND ANALYTICS AND OF
COURSE DRIVING FROM THE DATA
PLATFORMS IS AI IS THE VALUE WE
CAN GET FROM AI.
SO HERE'S HOW WE'RE STRUCTURED.
I'VE BEEN HERE FOR NOW A YEAR
AND I MONTH, ABOUT 8 MONTHS AGO
OR SO I WAS ASKED TO TAKE ON A
NEW ROLE IN THE DIRECTOR'S
OFFICE AS THE ASSOCIATE DIRECTOR
OF IT CYBER INFRASTRUCTURE AND
CYBERSECURITY, THAT MAKES AND I
REPORT TO THE DIRECTOR, THAT
MAKES ME LEAD BOTH THE OFFICE OF
THE CIO, AS WELL AS THE CENTER
FOR INFORMATION TECHNOLOGY, CIT
IS 1 OF THE 27 INSTITUTES AND
CENTERS OF THE NIH AND SUPPORTS
A BROAD RANGE OF ENTERPRISE
TECHNOLOGY SERVICES THAT SUPPORT
ALL THE THINGS THAT NIH DOES AS
WELL AS OTHER OPDIFS WITHIN
OTHER OPERATING DIVISIONS WITHIN
HEGHT AND HUMAN SERVICES.
WE'VE BEEN BUILDING AN
OUTSTANDING LEADERSHIP TEAM OVER
THAT TIME PERIOD.
WE RECENTLY RECRUITED ADELL
MERIT TO BE THE NIH'S CHIEF
INFORMATION OFFICER.
SHE COMES TO US FROM THE
NATIONAL INTELLIGENCE COMMUNITY
AS THEIR COMMUNITY CIO SO SHE'S
VERY FAMILIAR WITH WORKING IN AN
ENVIRONMENT LIKE WE HAVE AT THE
NIH WHERE WE HAVE MULTIPLE
INSTITUTES AND CENTERS AND BUILD
THEIR OWN APPROPRIATIONS AND
BUILD THEIR TOOLS AND PLATFORMS
AND TOOLS AND SHE HAS DONE AN
OUTSTANDING JOB OF REALLY
WRANGLING BOTH THE OFFICE OF THE
CIO AND CHIEF OF OFFICE OF
SECURITY OFFICE.
SHE DOES IN HER OFFICE SHE
FOCUSES ON STRATEGY FOR IT,
ENTERPRISE ARCHITECTURE, THOSE
ARE THE THINGS WE DO TOGETHER,
GOVERNANCE FOR IT, HOW WE MAKE
CAPITAL INVESTMENTS AND IN IT
AND ALSO INFORMATION SECURITY
HOW WE PROTECT OURSELVES FROM
THREATS.
WE ALSO HAVE THE CENTER FOR
INFORMATION TECHNOLOGY, I WAS
VERY EXCITED TO BE ABLE TO
ANNOUNCE IVOR, DE'SOUZA WHORKS
IS THE DEPUTY DIRECTOR OF CIT,
HE COMES TO US FROM THE CIO FROM
THE NATIONAL LIBRARY OF MEDICINE
AND HE REALLY PROVIDES
OPERATIONAL LEADERSHIP TO ALL
THE THINGS THAT CIT SUPPORTS
OOSES THE ENTERPRISE.
CIT IS ABOUT 1300 PEOPLE AND WE
SUPPORT EVERYWHERE FROM OUR
NETWORK TO OUR TEAMS, LICENSES,
TO OUR E-MAIL, AND HOSTING AND
STORAGE, OUR DATA CENTER, AND
OTHER KINDS OF APPLICATIONS AND
BUSINESS SYSTEMS THAT SUPPORT
NIH ACTIVITY.
WHEN I TALK ABOUT CYBER
INFRASTRUCTURE THAT WILL BE A
COMMON THEME FOR THIS
PRESENTATION, I THINK IT ORDER
TO SUPPORT BIOMEDICAL RESEARCH
WE HAVE TO ACKNOWLEDGE HOW
RESEARCH WORKS AND WE TEND TO BE
VERY FEDERATED IN OUR APPROACH,
SOMETIMES EVEN SILOS AND
BIOMEDICAL RESEARCH LABS TEND TO
DO THEIR OWN THINGS GR FEDERAL
REASON.
SO WE HAVE BEEN WORKING WITH ALL
OF THE ICs AND I REALLY WANT
TO HIGHLIGHT THE ROLE THAT CIT,
THE OFFICE OF THE CHIEF
INFORMATION OFFICER, THE
NATIONAL LIBRARY OF MEDICINE,
AND SUSAN GREGORIC'S OFFICE, THE
OFFICE OF DATA SCIENCE STRATEGY
PLAYS IN BOTH FUNDING AND YOU
KNOW DEVELOPING THE TECHNOLOGY
OF THE DIGITAL ECOSYSTEM THAT IS
GOING TO SUPPORT, YOU KNOW
TODAY'S NIH BUT ALSO SUPPORT THE
NIH IN THE FUTURE AND THEN EVERY
SINGLE INSTITUTE, WITHIN THE NIH
HAS THEIR OWN KIND OF PLATFORMS,
THEIR OWN TOOLS AND MY OPEN IS
THAT IN THE FUTURE THAT THOSE
THAT YOU KNOW THAT THEY WILL
LEVERAGE THE PLATFORMS AND TOOLS
THAT ARE BUILT YOU KNOW FROM
CIT, YOU KNOW FROM CIT THAT CAN
KIND OF HELP US DO BIOMEDICAL
RESEARCH, YOU KNOW MORE
IMPACTFULLY, BUT ALSO YOU KNOW
HOPEFULLY MORE EFFICIENTLY AS
WELL.
WE CAN TALK ABOUT THE SCOPE AND
SAMPLE OF WHAT WE DO.
THE NIH IS MORE THAN
400,000-MILES OF NETWORK
CABLING, WE HAVE SUPPORT 700,000
VISITORS IN 200 NIEKS H BUILDING
ACROSS 9 GEOGRAPHIC LOITION
KACCTS AND THE NIH SUPPORTS ALL
COMMUNICATIONS WE DO CENTRALLY
WITHIN NIH AND REALLY THE CORE
THAT FORMS A LOT OF WHAT WE DO
IN TERMS OF IT.
FOR IN TERMS OF COLLABORATION
TOOLS WE SUPPORT MORE THAN 2 AND
HALF MILLION VIRTUAL MEETINGS,
LIKE THE MEETING WE'RE HAVING
TODAY ON TEAMS THROUGH OUR
LICENSES AND SUPPORT SYSTEMS, WE
SEND MORE THAN A BILLION E-MAILS
THROUGH THE NIH E-MAIL SYSTEM
AND WE HAVE MORE THAN A MILLION
GIGA BITES OF DATA WITHIN SHARE
POINT AND MICROSOFT 1 DRIVE.
WE ALSO SUPPORT RESEARCH
APPLICATIONS, PARTICULARLY HIGH
PERFORMANCE COMPUTER, WE HAVE A
HUNDRED THOUSAND PLUS CORE SURP
COMPUTER CALLED BIOWULF WHICH
SUPPORTS MORE THAN 1 MILLION CP
U HOURS PER MONTH.
THIS JUST CONTINUES TO IMP
PRESSIVE AND THIS IS JUST A
COUPLE OF EXAMPLES ACROSS OUR
TEAMS THAT HELP SUPPORT THE
THINGS THAT WE DO.
LET ME START AND TALK A LITTLE
BIT ABOUT 1 OF THOSE CORE
MODULES OF CORE PLATFORMS OF
CYBER INFRASTRUCTURE AND THAT IS
USE OF THE CLOUD THROUGH OUR
PARTNERSHIPS WITH CLOUD SERVICE
PROVIDERS SUCH AS AMAZON, GOOGLE
AND MICROSOFT.
WE FOUNDED BEFORE I GOT HERE THE
NIH STRIDES INITIATIVE, IT'S
HAVE WELL,A LINED WITH THE NIH
STRATEGIC PLAN FOR DATA SCIENCE
AND PURSUES A MODERN INTEGRATED
INTUITIVE EFFICIENT, SECURE AND
DATA DRIVEN TECHNOLOGY TO
SUPPORT BIOMEDICINE AND YOU KNOW
HOPEFULLY WITH ALL OF US
WORKING, YOU KNOW IN CONCERT TO
LEVERAGE A SINGLE PLATFORM FOR
USE OF THE CLOUD, WITH THOSE 3
CLOUD PARTNERS THAT WE CAN
GENERATE COST SAVINGS FOR THE
RESEARCH COMMUNITY TO GET
LEVERAGE, CLOUD PLATFORMS IN
TERMS OF WHAT THEY DO AND THAT
ALSO GIVES US STRONG
PARTNERSHIPS WITH THOSE
PROVIDERS THAT CAN ENABLE US TO
GET BETTER R&D FROM THEM, BETTER
SUPPORT AND HAVE MORE IMPACT.
I THINK THE STRIDES PROGRAM HAS
BEEN LARGELY SUCCESSFUL.
WE NOW HAVE MORE THAN
360 MILLION GIGA BITES OF DATA
WITHIN THE STRIDES UMBRELLA AND
WE SUPPORT MORE THAN 2500
RESEARCH PROGRAMS ACROSS THERE
AND BASICALLY EVERY TYPE OF DATA
YOU MIGHT IMAGINE IS SUPPORTED
-- IS NOW CURRENTLY SUPPORTED
WITHIN STRIDES OR LEVERAGED
WITHIN DRIVES.
MANY PROGRAMS, SOME ARE NHLBI
PROGRAMS THAT YOU WITHIN THE
STRIDES ARE WITHIN STRIDES
INCLUDING ALL OF US, AND OTHERS
THAT ARE ALL SHARED HERE AND
REALLY I THINK WE'RE SEEING AN
ECOSYSTEM OF THESE PLATFORMS ARE
BEING LEVERAGED AGAIN WITHIN
STRIDES, AND CIT IS VERY PROUD
OF OUR, YOU KNOW OUR ROLE WITHIN
STRIDES AND WE REALLY APPRECIATE
OUR PARTNERSHIP WITH THE OFFICE
OF DATA SCIENCE STRATEGY AND THE
ASSOCIATE DIRECTOR OR SUSAN
GREGORY IN HER LEADERSHIP IN
DEVELOPING AND KIND OF
IMPLEMENTING STRIDES.
SOMETHING I WANT TO MENTION IS
THAT YOU KNOW 1 OF THE THINGS
I'M EXCITED ABOUT IS THAT
STRIDES IS MORE THAN JUST
COMPUTING THAT'S VIRTUAL.
WE CAN BUILD UPON STRIDES TO DO
YOU KNOW NEW AND BETTER THINGS
THAT ARE MAYBE MORE THAN THE SUM
OF THEIR PARTS.
SO 1 OF THOSE AREAS THAT I'M
EXCITED ABOUT IS NIH CLOUD LAB.
IT'S AN EXPERIMENT THAT ENABLING
INVESTIGATORS TO BOTH BE ABLE TO
TRY THE CLOUD AND KIND OF LEARN
HOW TO USE IT BAH ALSO TO GET
TRAINING TO DO OTHER THINGS THAT
THEY MIGHT DO AND SO, AT THE
VERY HIGHEST LEVEL, A CLOUD LAB
IS $500 OF CREDITS AND 90 DAYS
OF FREE CLOUD USAGE BUT THROUGH
SUSAN'S OFFICE, 1 OF THE THINGS
THAT CLOUD LAB HAS DONE IS THAT
THEY'VE WORKED WITH A NUMBER OF
IDEA STATES, CTR TO DEVELOP
TRAININGS ABOUT HOW TO DO
BIO-INFORMATICS IN THE CLOUD AND
THINGS LIKE THAT, ALL THOSE
TRAININGS ARE AVAILABLE TO
INVESTIGATORS THAT ARE
LEVERAGING CLOUD LAB AND SO THAT
KIND OF ENABLING THIS COMPUTING
PLATFORM, TO NOT ONLY ENABLE
INVESTIGATORS TO GET ACCESS TO
IT, BUT THEN ONCE INVESTIGATORS
GET ACCESS TO IT, WE'VE GOT
RESEARCHERS AND TRAINERS
COLLABORATING TO DEVELOP
MATERIALS TO LEARN HOW TO USE
THAT.
AND WITHIN THAT WE ARE SEEING
MORE DATA REPOSITORIES THAT
SUPPORT, THAT ARE SUPPORTED
WITHIN THE CLOUD, IT ENABLING
EVERYWHERE FROM AI DEVELOPMENT
TO DATA SHARING AND MODEL
SHARING, WITHIN THE NIH, I THINK
THIS IS DATA THAT'S A YEAR OLD
OR SO.
WE INVEST ABOUT -- WE INVESTED
ABOUT 300 MILLION IN AI PROJECTS
OFFICIALLY IN FY23 AND ABOUT A
BILLION DOLLARS IN TOTAL SINCE
2019 AND THAT DOESN'T INCLUDE
F-LAST YEAR.
AND AS YOU MIGHT EXPECT THE
SHARE OF AI FROM THE TOTAL OF
NIH BUDGET HAS INCREASED
SIGNIFICANTLY SINCE 2019 AND YOU
KNOW THERE ARE NUMEROUS
INITIATIVES THAT SUPPORT
INVESTIGATION INTO AND
UTILIZATION OF AI METHODS.
I THINK THIS IS SUCH AN
INCREDIBLE AREA AND OPPORTUNITY
NOT SURPRISINGLY AND I THINK THE
GROWTH OF FUNDING HAS ALSO
CREATED COMPUTATIONAL DEMAND FOR
YOU KNOW COMPUTATIONAL DEMAND
FOR DOING RESEARCH.
SO WITHIN -- WITHIN THE CLOUD WE
HAVE A NUMBER OF DATA PLATFORMS
THAT ARE SUPPORTED THAT HAVE
BEEN RELATIVELY STANDARDIZED FOR
USE.
THERE ARE TOOLS YOU MAY HAVE
HEARD OF THEM, GEN3, TERRA,
CAVATICA, FOUNDRY, BRICS
SUPPORTS WITHIN CIT, AND THESE
TOOLS SUPPORT ANALYZING DATA,
SHARING DATA AND BUILDING UPON
THAT AND THESE -- AND WE SUPPORT
A NUMBER OF THESE SORT OF
PLATFORMS ACROSS THE NIH AND A
NUMBER OF THE COMMUNITIES IN A
FEW SLIDES A SHARED AGO AND IN
UTILIZING SLIDES IS USING 1 OF
THESE PLATFORMS AND THESE TOOLS
ENABLE THAT STANDARDIZATION.
I'M REALLY HOPEFUL THAT AS WE
CONTRIBUTE STANDARDS TO THE
TECHNOLOGIES HERE THAT WE REALLY
TAKE ON WHAT I CALL ENTERPRISE
THINKING, THAT IS WE THINK ABOUT
WHAT ARE THE KIND OF STANDARD
MAYBE BORING THINGS WE CAN PUT
IN PLACE TO MAKE IT MORE
EFFICIENT TO BUILD DATA
PLATFORMS AND DATA RESOURCES IN
THE FUTURE, EVERYWHERE FROM
STANDARDIZING HOW WE LOG INTO A
SYSTEM, HOW WE AUTHORIZE ACCESS
TO DATA, HOW WE -- THE CLOUD
PLATFORM THAT WE USE, YOU KNOW
THINGS LIKE THAT, ALL OF THE
BASIC KIND OF STANDARD
COMPONENTS CAN BE STANDARDIZED
AND EVERY TIME WE STANDARDIZE
THEM WE BASICALLY MAKE IT A
LITTLE BIT EASIER TO ACHIEVE OUR
GOALS AROUND DATA, DATA SHARING
AND SCIENCE AND ANALYSIS OF THAT
DATA.
ONE OF THOSE EXAMPLES IS THE
RESEARCH OFFICE SERVICE OR RAS,
A COMMON TASK IN COMPUTER
RESOURCES IS AUTHICATION, ONCE
WE GET INTO A SYSTEM, LOG INTO
THE SYSTEM, THE SYSTEM TRUSTS
OUR IDENTITY WE THEN NEED TO BE
AUTHORIZED TO CERTAIN TYPES OF
DATA.
FOR EXAMPLE WHEN I LOG INTO MY
E-MAIL, MY E-MAIL SYSTEM KNOWS
MY IEE, AUDIENCE DENTITY BUT I'M
ONLY AUTHORIZED TO SEE MY E-MAIL
I'M NOT AUTHORIZED TO SEE
ANYBODY ELSE'S E-MAIL AND THAT
AUTHORIZATION ALSO WORKS WITHIN
DATA RESOURCES AND THERE ARE
STANDARD APPROACHES TO
DEVELOPING AUTHENTICICATION AND
AUTHORIZATION TOOLS.
SO FOR EXAMPLE, WE USE GA4G H
STANDARDS AROUND AUTHORIZATION
TO WOULD ENABLE AUTHORIZATION
ACROSS MULTIPLE DATA RESOURCES
THAT ARE MANAGED BY MULTIPLE
INDIVIDUALS THAT WOULD ENABLE AN
INVESTIGATOR TO GET ACCESS TO
THOSE MULTIPLE DATA SETS THEY'RE
AUTHORIZED TO SEE ACROSS
RESOURCES AGAIN USING THAT
STANDARD.
THIS IS A WONDERFUL
COLLABORATION BETWEEN THE OFFICE
OF DATA SCIENCE STRATEGY AND CIT
AND RAS IS 1 OF THOSE LEGOS THAT
I'M TALKING ABOUT WHERE WE'RE
TRYING TO CONTRIBUTE HORIZONTAL
PLATFORMS THAT CAN BE USED BY
EVERYBODY, THAT CAN ENABLE US TO
GET ACCESS TO DAT AND TO MANAGE
INDIVIDUAL RESEARCHER IDENTITIES
FROM DATA RESOURCES THAT WE
DON'T HAVE TO REINVENT THE WHEEL
EVERY SINGLE TIME WE DO THIS.
WORK SPACE IS SOMETHING THAT'S A
VERY HOT TOPIC FOR US RIGHT NOW.
WE WANT TO BE ABLE TO CREATE
WHAT I WOULD CALL SAND BOXES OR
ENCLAVES IN THE CLOUD THAT CAN
LEVERAGE DATA SETS FOR MULTIPLE
RESOURCES AND WE WANT TO BE ABLE
TO PROVIDE THESE ANALYTICS TOOL
BOXES TO AN INVESTIGATOR IN A
WAY THAT THEY'RE FAMILIAR WITH
CNET, SO IN OTHER WORDS IF THE
INVESTIGATOR WANTS TO DO GENOME
ANALYSIS ON SAY A HUNDRED
THOUSAND GENOMES, AND THEY HAVE
COMPUTATIONAL TOOLS TO DO THAT,
WE WOULD LIKE TO BE ABLE TO SPIN
UP, WHAT I WOULD LIKE TO SAY
SPIN UP AT A COMPUTER
ENVIRONMENT IN THE CLOUD, GIVE
THEM ACCESS TO IT, AND THEN
ENABLE THEM TO HAVE ACCESS TO
THE HUNDRED THOUSAND GENOMES
EVEN THOUGH THEY MAY NOT BE CO
LOCATED WITHIN THE SAME
ENVIRONMENT AND THEN HAVE THE
ANALYTICS TOOLS THEY NEED IN
FRONT OF THEM TO BE ABLE TO DO
THAT ANALYSIS.
THERE ARE A NUMBER OF STANDARD
PLATFORMS THAT ENABLE THESE KIND
OF CLOUD-LIKE SAND BOXES, YOU'VE
PROBABLY HEARD SOME OF THEM
EVERYWHERE FROM P A LANTIR,
GALAXY, DNANNEXUS, FLY WHEEL,
AND THIS IS WHERE WE LIKE PEOPLE
TO GO TO BE ABLE TO PROVIDE A
LITTLE BIT MORE OF THAT SAND BOX
AS A SERVICE WE CAN PROVIDE TO
INVESTIGATORS THAT WANT TO DO
ANALYSIS IN THE CLOUD IS THAT WE
CAN CREATE NASCENT ADHOC
ENVIRONMENTS FOR A RESEARCHER TO
DO THE KIND OF WORK THEY NEED TO
DO TO SOLVE THE KIND OF PROBLEMS
THAT I NEED TO SOLVE QUICKLY AND
EFFICIENTLY.
SO OUR HOPE IS IN THE FUTURE
THIS WOULD BE PLUG AND PLAY, IT
WILL BE STANDARDIZED AND IT WILL
BE EASY TO DO WITH SUPPORT AND
GROWING NIH DATA ECOSYSTEM WHERE
IF YOUR USING THE STANDARD
PLATFORMS, OF WHICH, YOU KNOW
FOR EXAMPLE, NHLBI DOES AND IS A
HEAVY USER OF THAT YOU WILL BE
ABLE ON ENABLE INVESTIGATORS IN
THE FUTURE TO BE ABLE TO GET
ACCESS TO DATA AND DO THAT KIND
OF ANALYSIS THEY WANT TO DO,
AGAIN, VERYENTIOUS FICIENTLY IN
THE CLOUD AND HOPEFULLY
INEXPENSIVELY AS WELL.
THERE ARE MANY NIH PROGRAMS THAT
ARE ALREADY USING WORK SPACES,
AND AGAIN, WE'RE WORKING TO
STANDARDIZE THAT AND HERE ARE
JUST A FEW EXAMPLES OF THEM ON
THIS SLIDE.
SOMETHING THAT I'M ALSO
INTERESTED IN, I'M ALSO AN
INVESTIGATOR, YOU PROBABLY SAW
THIS YEAR THAT THE NOBEL PRIZE
IN CHEMISTRY WAS AWARDED TO A
NUMBER OF INVESTIGATORS THAT YOU
KNOW SOLVE THE PROTEIN STRUCTURE
PREDICTION PROBLEM USING
COMPUTATIONAL METHODS AND I
THINK IT'S REALLY IMPORTANT TO
GIVE CREDIT TO THE CRITICAL
ASSESSMENT OF STRUCTURE
PREDICTION.
I DON'T KNOW HOW MANY OF YOU ARE
FAMILIAR WITH THIS BUT THIS IS
AN ANNUAL CHALLENGE THAT'S BEEN
HAPPENING SINCE THE EARLY 90S
WHERE THE COMMUNITY OF
SCIENTISTS GOT TOGETHER THAT
WERE TRYING TO SOLVE THE PROTEIN
STRUCTURE PREDICTION PROBLEM AND
SAID, WE NEED TO HAVE AN
UNBIASED WAY TO ASSESS EVERY
YEAR OR EVERY 2 YEARS ACTUALLY
WHETHER -- HOW CLOSE OUR
COMPUTATIONAL METHODS WERE
GETTING TO SOLVING THIS VERY
CHALLENGING PROBLEM.
THIS WAS FUNDED BY NI GMS AND
EVERY 2 YEARS, THE CASP
COMPETITION WOULD ANOWBS THAT
WE'RE GETTING CLOSINGER AND
CLOSER TO SOLVING THE STRUCTURE
PREDICTION PROBLEM AND IT WAS
THEN THAT WE WERE ABLE TO
ANNOUNCE THAT IT HAD BEEN SOLVED
IN A WAY THAT WAS ABLE TO EBABLE
THOSE INVESTIGATORS TO RECEIVE
THE NOBEL PRIZE, THAT'S DAVID
BAKER'S GROUP AND THE ALPHA FOLD
TEAM.
SO I REALLY LIKE THESE SORT OF
COMMUNITY DRIVEN APPROACHES
WHERE COMMUNITIES AND
INVESTIGATORS GET TOGETHER AND
SAY, WE'RE GOING TO TRY TO SOLVE
A CERTAIN PROBLEM IN A VERY
STANDARDIZED WAY AND I THINK WE
CAN REALLY DEMONSTRATE THAT
THESE PROBLEMS CAN BE -- CAN
HELP US SOLVE, YOU KNOW
CHALLENGING PROBLEMS FOR EXAMPLE
IN ARTIFICIAL INTELLIGENCE.
WE ALSO HAVE A NUMBER OF
BUSINESS CASES OF USE OF AI IN
-- WITHIN THE NIH, I THINK I
WILL TALK A LITTLE BIT MORE
ABOUT THIS IN A SECOND, FOR
EXAMPLE, WE HAVE A TOOL CALLED
TRIAL GPT USED IN THE CLINICAL
SPACE WHERE WE ARE MATCHING
PATIENTS USING CLINICAL TRIALS
USING CLINICAL DATA AND THIS IS
SOMETHING THAT'S OPERATIONAL AND
CAN YOU KNOW HOPEFULLY ASSIST
HEALTHCARE IN DEVELOPING PATIENT
MATCHING WHICH IS A CHALLENGING
PROBLEM.
TO THAT RESPECT, WE HAVE A
NUMBER OF OTHER OPERATIONAL AI
PROJECTS THAT ARE GOING ON HERE
THAT ARE NOT RESEARCH, WE'VE
ENTERED A NEW AGE I THINK THAT
RESEARCHERS ARE STARTING TO
APPRECIATE THAT AND THAT IS THAT
AI IS NOW OPERATIONAL WE ARE
SEEING IT IN OUR COMMON LIVES
THAT ARE IMPLEMENTED WITH
ADVANCED DATA SCIENCE AND IT'S
LIKE PUTTING IN PLACE SOFTWARE
SO WE'RE FOR EXAMPLE, SEEING
THINGS LIKE MICROSOFT CO PILOT
THAT'S SUMMARIZING E-MAILS.
IF YOU HAVE AN APPLE IPHONE AND
THEY HAVE APPLE INTELIENCE CAN
AND THEY HAVE SIRI TALK TO YOU
AND TELL YOU AND TALK TO YOU
THINGS BASED ON A LARGE LANGUAGE
MODEL, SO WE'RE SEEING THIS
EVERYWHERE, IT'S GOING TO
CONTINUE TO GROW, THERE ARE A
NUMBER OF BENEFITS OF
IMPLEMENTING THIS, BUT THERE ARE
ALSO RISKS AS YOU ALL KNOW, AI
CAN BE INEQUITABLE, WITH DATA
COMPANIES OUTSIDE OF YOUR
ENTERPRISE AND THAT DATA YOU
SHARE MAY BE USED TO TRAIN
MODELS.
AI CAN IMPACT HUMAN RIGHTS, IT
CAN BE UNSAFE, DRIFT IN ACRASE
MODEL EXPE MANY DATA PRIVACY
ISSUES SO WE NEED TO BE CAREFUL
AND IN THE USE OF AI AND SO WHAT
WE THINK IS GOVERNANCE HOW WE
IMPLEMENT OPERATIONAL REMARKS I
INTO THE NIH ECOSYSTEM FOR FOR
OPERATIONAL USE, IT COULD BEING
WEB SERVICES SUCH AS CHAT GPT ET
CETERA AND WE'VE RECENTLY
LAUNCHED A SECURE CHATGPT TO THE
NIH'S INTRAMURAL RESEARCH
COMMUNITY PROGRAM WHICH IS
CHIRP, WHICH IS CHAT FOR THE
IRP, AND NOW TODAY USERS CAN BE
TRAINED.
THEY CAN ATTEST TO NOT SHARING
NIH CONFIDENTIAL INFORMATION AND
THEN THEY WILL GET ACCESS TO A
WEB SERVICE THAT ENABLING THE
LATEST AND GREATEST CHATGPT
MODELS AND I THINK IT'S REALLY
IMPORTANT TO EMPHASIZE THAT
OVERSIGHT OF THIS IS NECESSARY
JUST LIKE WE OVERSEE OTHER IT
SYSTEMS, YOU KNOW IN TERMS TO
INSURE THAT WE ARE RESPONSIBLY
YOU KNOW IMPLEMENTING AI AND
DOING IT IN THE APPROPRIATE WAY
AND THEN CLINICAL ACTIVITIES
WHETHER IT BE CLINICAL TRIALS OR
WORK THAT WE DO AT THE CLINICAL
CENTER, YOU KNOW COULD BE
IMPLEMENTED IN SUCH A WAY THAT
YOU KNOW CAUSES PATIENT OR
CLINICAL HARM.
>> TODAY THERE'S ALMOST 195 USE
CASES WITHIN THE NIH THAT ARE
OPERATIONAL AI OF OF THEM 77 OF
THEM ARE OPERATIONAL TODAY AND
INCLUDE USES SUCH AS LARGE
LANGUAGE MODELS SO WE ARE A VERY
HEAVY USER OF ARTIFICIAL
INTELLIGENCE OPERATIONINGS TODAY
AND I EXPECT THIS WILL CONTINUE
TO GROW.
SO FOR EXAMPLE WE HAVE AN LLM
PROGRAM, AND THEY CAN USE AND
STREAMLINE THE REVIEW PROCESS
AND SEE THE DMS PLANS THAT COME
FORWARD.
I MENTIONED CHIRP ALREADY AND IT
WAS LAUNCHED JUST A FEW MONTHS
AGO, WE HAD ALMOST 600 PEOPLE
ATTEND THE CHIRP LUNCH EVENT SO
THIS IS JUST WITHIN THE IRP, SO
IT'S VERY, VERY POPULAR AND
USEFUL WITHIN THE NIH COMMUNITY
AND CO PILOT IS COMING, THIS IS
SOMETHING THAT'S VERY MUCH IN
DEMAND, IT'S LLM CONNECTED TO
E-MAIL AND TO TEAMS AND CAN DO
THINGS LIKE SUMMARIES AND WITHIN
THE FEDERAL GOVERNMENT, WE HAVE
TO USE THE FED RAMPED, THE
BASICALLY THE CO PILOT THAT IS
IN THE FEDERAL CLOUD, THAT'S
BECOMING AVAILABLE HERE AND NOW
IN APRIL AND WE WILL SEE IT
BEING ROLLING OUT -- ROLLING OUT
SHORTLY FOR PEOPLE WITHIN THE
NIH COMMUNITY TO USE.
ALL RIGHT, SO I'M JUST GOING TO
FINISH UP NOW, I THINK I'M
ALMOST OUT OF TIME, I MENTIONED
SEVERAL TIMES THAT WE REALLY
THINK ABOUT COMPUTING
INFRASTRUCTURE LIKE LEGOS, THAT
WE WANT TO PUT IN OPEN REUSABLE
TOOLS THAT SCIENTISTS CAN PULL
OFF THE SHELF AND USE AND THAT
BY USING THOSE TOOLS THEY BOTTOM
MORE STANDARDIZED AND MORE
ALIGNED WITH FOR EXAMPLE OUR
DATA SCIENCE STRATEGY.
AND THESE TOOLS CAN BE ANYTHING
THAT YOU MIGHT IMAGINE THAT
COULD BE USEFUL, IT'S NOT JUST
COMPUTING VIERPTS FOR LOGGING
IN, BUT IT COULD BE SPECIALIZED,
POWER INFORMATICS ANYTHING WE DO
AND MY HOPE IS THAT WE WILL
CONTINUE TO BUILD AND THINK
ABOUT THAT ECOSYSTEM OF THESE
LEGO BLOCKS THAT CAN BE PUT
TOGETHER AND DO THINGS.
SO WE ARE REALLY TRYING TO BUILD
THIS TECHNICAL GARDEN, AND YOU
KNOW KIND OF HERE'S WHAT MY
INTERESTS ARE IN THE FUTURE.
WE WANT TO REALLY SUPPORT
ADVANCING CLINICAL RESEARCH AND
TRIALS WITH TECHNOLOGY, WE WANT
TO DEVELOP NIH'S ADMINISTRATIVE
STRATEGY, SUPPORT TECH CAREERS
WITH WITHIN THE NIH AND
OPERATIONAL AI WITHIN THE NIH
AND WE WANT TO HELP ENTERPRISE
NIH SYSTEMS WITHIN THE CLOUD SO
THIS IS ALL OF THE THINGS THAT
WE EXCLUSIVELY WANT TO DO WITHIN
THE NIH, WHEN WE THINK ABOUT
OUTSIDE TO THE BROADER FOCUS ON
THE BIOMEDICAL RESEARCH
COMMUNITY, WE'RE REALLY FOCUSING
ON LEVERAGING AND LEADING THE
BIOMEDICAL SCIENCES -- THE
BIOMEDICAL SCIENCES TECHNICAL
COMMUNITY WILL RUN A SESSION AT
ISMB IN LIVER POOL THIS SUMMER
AND WILL BE DOING A WORKSHOP AT
THE PACIFICS SYMPOSIUM IN
BIOCOMPUTING NEXT JANUARY WHERE
WE ARE TRYING TO BRING TOGETHER
PEOPLE WHO WILL BE BETTER FLUENT
IN THE KINDS OF TOOLS WE ARE
LOOKING AT TODAY AND THEN WE ARE
CONTINUING TO SUPPORT USE OF THE
CLOUD BY RESEARCHERS AND
IMPROVING WHAT WE CALL FLUENCY
IN TERMS OF USE OF TECHNOLOGY
DATA.
WE HAVE A BROAD NEWS LETTER
THAT'S COMING OUT, YOU WILL SEE
IT, BEST PLACE TO FOLLOW IT
WOULD BE ON LINKEDin FROM ME
OR 1 OF MY STAFF AND YOU WILL
SEE IT SHARED THERE BUT CAN YOU
ALSO JUST REGISTER WITH AN
E-MAIL ONCE YOU SEE IT COME OUT.
IT SHOULD COME OUT HERE SHORTLY,
THE FIRST 1.
SO I WANT TO FINISH THERE AND I
WANT TO THANK DR. GIBBONS AND
EVERYBODY AT NHLBI WHO GAVE ME
AN OPPORTUNITY TO PRESENT TODAY.
I HOPE IT'S BEEN INTRIGUING AND
I WILL BE HAPPY TO TAKE
QUESTIONS AND --I HOPEFULLY
DIDN'T GO TOO LONG.
THANK YOU VERY MUCH.
>> THANK YOU, SEAN.
SO I WILL OPEN IT UP, I SEE A
HAND IS THAT YOU DR. REDLINE?
>> THAT WAS INTERESTING, THANK
YOU VERY MUCH.
IS CHIRP SOMETHING THAT MIGHT BE
AVAILABLE OUTSIDE OF THE NIH
ITSELF TO NIH INVESTIGATORS?
>> GOOD QUESTION.
I DON'T -- THAT'S A MORE COMPLEX
QUESTION TO ANSWER THAN I CAN
ANSWER RIGHT NOW BUT I CAN
FOLLOW UP ON THAT.
WE DO WOULD LIKE TO PROVIDE THE
SERVICES THAT WE PUT IN THE
CLOUD TO BE MADE AVAILABLE
BROADLY, YOU KNOW, I THINK OF
TECHNICAL TOOLS, I LIKE TO CALL
THEM HORIZONTAL, I WANT THEM
MADE AVAILABLE TO BE USED BY
EVERYBODY BECAUSE ONCE WE SILO
WE CREATE OTHER TYPES OF SILOS
LIKE DATA SILOS.
BUT IN TERMS OF CHIRCH, YOU HAE
TO THINK OF WORK TO DO THAT
BECAUSE OF THE FACT THAT IT'S IN
THE FEDERAL CLOUD ENVIRONMENT.
THE SOFTWARE IS CERTAINLY
INTEROPERABLE, THE SOFTWARE
COULD BE PUT INTO OTHER -- YOU
KNOW TO TALK TO OTHER CHAT GPT
APIs SO THAT MAY BE POSSIBLE
IN THE FUTURE.
>> DOCTOR?
>> GREAT.
MAYBE YOU CAN STOP SHARING?
>> YEAH.
>> SO THANK YOU FOR THE TALK.
IT WAS REALLY INTERESTING, I'M
SITTING HERE AT YOUR ALMA MATER
IN MADISON WHICH IS ALSO AS YOU
KNOW THE HOME OF THE EPIC, AND 1
OF THE THINGS THAT WASN'T
MENTIONED IS HOW INTERACTIONS
WITH THE EHR AND ARE THERE ANY
ONGOING DISCUSSIONS WITH EPIC OR
OTHER MAINLY EPIC TO REALLY
UTILIZE THAT RICH RESOURCE FOR
CLINICAL TRIALS FOR SO MUCH
INFORMATION IN THERE.
>> YEAH, SO EPIC AS YOU KNOW IS
RELEASING MODELS THAT CAN BE
IMPLEMENTED WITHIN THE IHR, THEY
ARE EVERYWHERE FROM LIKE AMBIENT
SCRIBE LIKE MODELS THAT HELP TRY
TO DRAFT DOCUMENTATION.
MY CHART HAS THESE INBOX MESSAGE
RESPONDER TO PROVIDERS THROUGH
MY EXPHART THERE'S A BUNCH OF
OTHER THINGS, PREDICTION OF
SEPSIS HAS BEEN IN PUBLICATIONS
A LOT.
I WILL GIVE YOU A SIDE ANSWER,
I'M NOT PERSONALLY TALKING TO
EPIC, I USED TO GO TO LIKE ALL
THE EPIC UG OR CAN'T REMEMBER
THE NAME OF THE EVENTS, I HAVE
TO SAY, I THINK WE NEED TO DO
PERHAPS A BETTER JOB OF
ECTOMYOSIN KLF-TWOING REAL WORLD
DAT ON THE UUTILIZATION OF AI
AND HOW IT AFFECTS CARE AND
OPERATIONS OF HEALTHCARE.
WE HAVE MOST EPIC SITES, HAVE
IMPLEMENTED FOR EXAMPLE,
DRAFTING MY CHART MESSAGES AND I
WOULD BE VERY INTERESTED, I
THINK WE SHOULD STUDY AND GIVE
OPPORTUNITIES FOR INVESTIGATORS
TO HAVE ACCESS TO AND STUDY, YOU
KNOW HOW -- HOW THOSE RESPONSES
MIGHT BE DIFFERENT FROM LIKE A
-- YOU KNOW A RESPONSE THAT
DIDN'T HAVE A DRAFT PRESENTED TO
THE PROVIDER AND THINGS LIKE
THAT SO I JUST THINK THAT AS WE
IMPLEMENT AI, IT'S IMPORTANT
THAT WE COLLECTED KIENTS OF DATA
TO STUDY THAT, LIKE OUTCOMES
DATA.
IN MY PREVIOUS ROLE, NOT AT THE
UNIVERSITY OF WISCONSIN, I WAS
CAREFUL TO ASK QUESTIONS LIKE,
WE'VE ENACTED THIS PREDICTOR OF
SEPSIS AND IT'S BEEN ACTIVE FOR
2 MONTHS AND CAN YOU NOW TELL ME
WHO GOT IT AND HOW DID WE
PREDICT IT IN AND SIMPLE
QUESTIONS LIKE THAT ARE VERY,
VERY HARD TO ASK AND COLLECT DAT
ON.
SO INDUSTRY WILL IMPLEMENT A LOT
OF AI AROUND US AND AS
RESEARCHERS IT'S OUR
RESPONSIBILITY TO COLLECT THAT
AND RESEARCH THE IMPACT OF THAT
AS WE DO WITH OTHER THINGS.
>> THE OTHER PART OF MY QUESTION
WAS BEING ABLE TO ACCESS ALL THE
DATA THAT EXISTS IN THE EHR TO
ANSWER QUESTIONS.
>> XCTLY.
AND WE NEED TO DO A BETTER JOB
OF STANDARDIZING THE KIND OF
DATA WE COLLECT, SO THAT WE CAN,
YOU KNOW LIKE THE SEPSIS
EXAMPLE, LIKE ACTUALLY NO, WHO
GOT SEPSIS, WHEN THEY GOT SEPSIS
AND WHETHER SOMETHING PREDICTED
THAT THEY GOT SEPSIS OR NOT.
THANK YOU FOR THE QUESTION.
>> THANK YOU.
GEORGE?
>> SEAN THIS, , THIS IS GEORGE I
WAS EXCITED TO HEAR ABOUT THE
WORK AND THE SAND BOXES AND THE
WORK OF COMMUNITY BUT I HAVE A
SENSE YOU'RE TALKING ABOUT THE
COMMUNITY OF SCIENTISTS, IT
WOULD BE GREAT IF YOU COULD
SHARE WITH US ABOUT HOW YOU
THINK ABOUT COMMUNITIES IN
INDIVIDUALS PARTICULARLY IN
RURAL AREAS, SOCIAL AND
ENVIRONMENTAL DETERMINANTS MAY
IMPACT THEIR LIVES AND MAY NOT
BE CAPTURED IN EHRs, HOW ARE
WE THINKING ABOUT MOVING FORWARD
WHEN IT COMES TO THAT?
>> YEAH, WE WERE JUST TALKING
ABOUT THIS IN THE PREVIOUS
QUESTION ABOUT HOW CLINICAL DATA
IS LIMITING.
I THINK WE NEED TO BOTH IMPROVE
CLINICAL DATA.
I THINK THE HEALTHCARE WORLD IS
STARTING TO COLLECT OTHER TYPES
OF DATA BUT WHEN WE DO RESEARCH
WE WANT TO BE ABLE TO HAVE
ACCESS TO BROAD SPECTRUMS OF
DATA THAT FIT THE KINDS OF
STUDIES THAT WE'RE DOING AND
THAT MEANS, YOU KNOW BEING
INCLUSIVE OF COMMUNITIES THAT
MAY NOT NORMALLY PARTICIPATE IN
RESEARCH OR HAVE ACCESS TO THE
KINDS OF TECHNOLOGIES THAT I'M
TALKING ABOUT HERE TODAY, BUT I
THINK IT ALSO MEANS BEING
CREATIVE ABOUT HOW WE INTEGRATE,
AGAIN, RESPONSIBLY AND ETHICALLY
INTEGRATE, YOU KNOW KIND OF
DESPERATE DATA SETS TOGETHER TO
BE ABLE TO MAXIMIZE OUR ABILITY
TO YOU KNOW TO DO STUDIES, YOU
KNOW PERHAPS AT THE POPULATION
LEVEL AND YOU KNOW I THINK WE'VE
SEEN A NUMBER OF DIFFERENT
APPROACHES THAT INVESTIGATORS
ARE TAKING, SOME ARE REALLY,
REALLY INNOVATIVE AND A LOT OF
THAT IS ROLLING YOUR SLEEVES UP
AND GETTING THAT DATA OF OUR
ABILITY TO LINK DAILY BASIS THEA
SETS USING TECHNOLOGIES LIKE
PRIVACY PRESERVING RECORD
LINKAGES BUT ALSO, YOU KNOW BUT
ALSO, YOU KNOW HAVING THE
APPROPRIATE KIND OF DATA USE
AGREEMENTS OR PARTNERSHIPS WITH
THE USE OF THOSE DATA SO WE CAN
AGAIN DO THE RESEARCH WE DESIRE
TO DO TO HAVE AN IPT GREATER
-- IMPACT, BUT
I DON'T THINK IF THAT ANSWERS
YOUR QUESTION BUT IT'S AN
IMPORTANT ISSUE AND I THINK A
LOT OF THAT COMES DOWN TO REALLY
MAKING SURE WE HAVE THE RIGHT
DATA AND THAT WE HAVE YOU KNOW
RESPONSIBLE ACCESS TO IT.
>> GREAT.
THANK YOU.
>> ANYTHING ELSE FOR DR. MOONEY?
OKAY, HEARING, SEEING NO HANDS
RAISED, I WANT TO THANK YOU FOR
YOUR TIME, VERY THE VERY THOUGHT
PROVOKING PRESENTATION.
>> THANK YOU AND I'M SORRY I'M
NOT THERE IN PERSON.
>> THANK YOU VERY MUCH FOR
JOINING US.
OKAY, SO AS WE CONTINUE ON OUR
NEXT PRESENTATION, I WILL GIVE
YOU AS WE'RE REQUIRED TO BRING
TO COUNCIL CONTINUING THE THEME
OF AI.
I WANT TO SHARE WITH YOU THE
INSTITUTE'S PLAN OF ESTABLISHING
AN AI WORKING GROUP, IF I CAN
HAVE THE SLIDES UP, PLEASE.
SO WELCOME YOUR FEEDBACK ON THE
PLANS THAT I WILL SHARE WITH YOU
ONCE I FINISH WITH THE
PRESENTATION.
SO WE'RE INTENDING TO ESTABLISH
AN ARTIFICIAL INTELIENCE WORKING
GROUP OF COUNCIL.
NEXT SLIDE.
SO AS YOU KNOW BIOMEDICAL
RESEARCH IS OBVIOUSLY
INCREASINGLY DATA INTENSIVE, THE
INSTITUTE HAS ESTABLISHED ITS
THAT WERE PROGRAMMED AND
RESOURCES AND TOOLS THAT PUT US
IN A SPACE THAT WE CAN -- WE
WOULD LIKE TO NOW LEVERAGE SOME
OF THIS, SO THAT WE CAN HARNESS
AND DEVELOP THE DATA SCIENCE
APPROACHES TO ANALYZE THIS DATA.
SO AS WE ARE MOVING FORWARD,
WHAT WE ARE PROPOSING IS TO
ESTABLISH THIS WORKING GROUP AND
SO INTERNALLY, IN PREPARING TO
ESTABLISH THE WORKING GROUP,
WE'VE ALSO LEVERAGED
DR. GOFF AND I HAVE LEVERAGED A
TEAM OF EXPERTS WITHIN THE
INSTITUTE INCLUDING THE
INTRAMURAL PROGRAM TO HELP US
BEGIN THINKING ABOUT THE CHARGE
FOR THIS WORKING GROUP.
SO WHAT I'M PRESENTING TO YOU
HERE IS THE PROPOSED CHARGE THAT
WAS DEVELOPED BY THE INTERNAL
STAFF OF EXPERTS.
SO WE WISH TO ESTABLISH, OUR
INSTITUTE ESTABLISH AI WORKING
GROUP OF THE ADVISORY COUNCIL TO
EFFECTIVELY AND EFFICIENTLY
CAPITALIZE ON AI AND ML, ADVANCE
THE INSTITUTE'S MISSION ALONG
WITH AGENCY PRIORITIES, TO DRIVE
RAPID AND SUSTAINABLE ADVANCES
IN HEART, LUNG, BLOOD AND SLEEP
RESEARCH HEALTH THE AI WORKING
GROUP CHARGE WE ARE ASKING THEY
WILL BECOME FAMILIAR WITH THE
INSTITUTE'S CURRENT PORTFOLIO IN
AI, IDENTIFY TIEWPTS FOR FUTURE
INVESTMENTS AND ENABLE
MAIPTINENCE OF AN EVERGREEN
PRIORITIZED LIST OF
RECOMMENDATIONS FOR STRATEGIC
INVESTMENTS, ADVISE US ON THE
IMPLEMENTATION STRATEGY TO
INSURE THAT NHLBI AI ENDEAVORS
ARE COORDINATED INTEGRATED AND
ALIGN WIDE INSTITUTE'S
PRIORITIES.
WE WERE ASKING IF THE WORKING
GROUP ONCE ESTABLISHED WOULD
OUTLINE A FRAMEWORK THE
INSTITUTE'S AVAILABILITY TO BE
ON THE VON GUARD OF SCIENTIFIC
LANDSCAPE WHILE AVOIDING
REDUNDANCY.
AS WE THINK ABOUT THIS ISSUES
THE MEMBERS WE ANTICIPATE THAT
THE MEMBERS SHALL CONVENE AND
DEVELOP A RAPID CYCLE BASIS FOR
THE ADVISORY COUNCIL AND WE WANT
TO EMPHASIZE THIS RAPID CYCLE
BECAUSE AGAIN AS DR. MOONEY
MENTIONED, THE TECHNOLOGY IS
DEVELOPING SO RAPIDLY WE WANT TO
MAKE SURE WE ARE THINK BEING
THIS AND BEING ABLE TO
CAPITALIZE ON SHORT-TERM
EMERGING BUT ALSO LOOK AUTOTHE
FOREFRONT BUT ALSO LOOKING FOR
LONG-TERM PLANNING AS WELL SO WE
WANT TO BE NIMBLE BUT WE ALSO
WANT TO PLAN FOR LONG-TERM.
AS WE THINK ABOUT THIS WORKING
GROUP AND THE EXPERTISE WE'RE
PROPOSING THIS SLIDE IS SHARING
WITH YOU BROAD LEVELS FOR TYPES
OF EXPERTISE, BOTH SCIENTIST AND
NONSCIENTIFIC EXPERTS WE WOULD
LIKE TO ENGAGE WITHIN THIS
PERSPECTIVE OF THE WORKING
GROUP.
SO OF COURSE AI ML APPLICATIONS
BEYOND THAT WE'RE LOOKING AT
SYSTEMS BIOLOGY, EXPERTISE,
CLINICAL TO INCLUE EHR, AND
IMAGING, EPISOME -- EXPOSOME,
EXCUSE ME, HEART AND LUNG BLOOD
INVESTIGATORS EXTRAMURAL AND
INTRAMURAL AND PRACTITIONERS AND
AS DR. MOONEY MENTIONED WE'RE
TALKING ABOUT COMMUNITY, NOT
ONLY THE RESEARCH COMMUNITY BUT
THE BROADER COMMUNITY OF
INDIVIDUALS BROADLY ACROSS THE
NATION THAT WOULD BE IMPACTED
AND MAY LEVERAGE SOME OF THESE
TOOLS, WE'RE ALSO LOOKING FOR
THOSE IN THOSE EXPERTISE IN THE
RESPONSIBILITY USE SO THINK
ABOUT THE ETHICAL USE OF AI ML
AND ALSO EXPERTS BEYOND
BIOMEDICINE.
IT'S NOT ADVANCING.
GO BACK, 1 SLIDE.
OKAY.
SO WHAT WE'RE PROPOSING IS AN
ITERATIVE PROCESS.
SO IN THE FIRST YEAR WE WOULD
ESTABLISH THE WORKING GROUP AND
WE PROPOSE A WORKSHOP AND THE
IDEA HAVING A WORKSHOP IS TO
EMPHASIZE THE DEVELOPMENT AND
EXECUTION OF THE PROGRAM, AND WE
ANTICIPATE THAT WE WOULD PROVIDE
THE WORKING GROUP MEMBERS AN
OVERVIEW OF THE SCIENTIFIC
PORTFOLIO, LARGE COHORT PROGRAMS
FOR EXAMPLE, TOP MED, BDC, ET
CETERA, HEART LUNG PROGRAMS
TARGETED AI MACHINE LEARNING
APPLICATIONS AND THEN WE WILL
ASK THEM IN THIS WORKSHOP TO
DISCUSS THE COVAGE OF OUR
PORTFOLIO, AND IRS DENTIFY GAP
AREAS AND ALSO ANTICIPATE THAT
THEY WILL ALSO PROVIDE GENERAL
RECOMMENDATIONS REGARDING OUR
APPROACH GOING FORWARD AND
PROVIDE A FRAMEWORK FOR IMPROVED
COORDINATION OF OVERALL AI/ML
PROGRAMS AND EFFICIENCIES.
SO THAT'S WHAT WE'RE
ANTICIPATING AT YEAR 1.
AND AS WE ESTABLISH THIS WORKING
GROUP, WE IMAGINE WE WOULD HAVE
A CORE OF WORKING GROUP MEMBERS
OF THE COUNCIL, BUT WE WILL
LEVERAGE EXPERTISE AS WE GO INTO
SUBSEQUENT YEARS, OF THE
ACTIVITIES, NEXT SLIDE.
LET'S SEE, SO WE LOOK AT YEAR 2
AND BEYOND.
AGAIN, WE WILL CONTINUE TO LOOK
AT KNOWN GAP AREAS AS WELL AS
EMERGING RESEARCH AND WORKFORCE
OPPORTUNITIES, WE WANT TO
LEVERAGE THESE PLATFORMS AND
SUBJECT MATTER EXPERTS, SO
AGAIN, WE WANT TO MAKE SURE
WE'RE NIMBLE AND THINKING ABOUT
THIS NOT AS 1 AND DONE BUT AS WE
WERE ABLE TO PIVOT AND LIVEERAGE
AND WE'RE ABLE TO FORECAST WHERE
WE MIGHT NEED TO GO, AND WE
WOULD LIKE TO HAVE THE WORKING
GROUP AS WE MOVE FORWARD
RECOMMEND ENHANCEMENTS AS WE GO
ALONG, SO WE MIGHT HAVE A BROAD
LIST OF ECMENDATIONS, SAY THAT
WOULD RESULT FROM THE FIRST
YEAR'S WORKSHOP, BUT WE WANT TO
MAKE SURE THAT WE ARE MAYBE
TARGETING AND MAYBE IN PARALLEL,
MAYBE IN SEQUENCE, DEPENDS ON
WHAT WE LEARN FROM THE WORKING
GROUP WE WANT TO MAKE SURE WE
DRILL DOWN ON TARGET AREAS WHILE
AT THE SAME TIME THINKING MORE
BROADLY AS WELL, SO WE WOULD
LIKE TO HAVE THE ABILITY TO
ADJUST AND BE NIMBLE AND AGAIN,
WE WANT TO MAKE SMUR WE HAVE
SHORT, MEDIUM AND LONG-TERM
APPROACHES.
SOPHISTICATED WITH THAT I WOULD
LIKE TO STOP AND THEN ASK THE
COUNCIL MEMBERS IF HAVE YOU ANY
QUESTIONS OR ANY COMMENTS OR
CONCERNS AROUND WHAT WE'RE
PROPOSING?
>> DR. REDLINE?
>> JUST A QUICK QUESTION, I
THINK THIS WAS NICELY SUMMARIZED
AND LOOKS LIKE A WONDERFUL WAY
FORWARD.
I CENTERED ON AMONG THE AREAS OF
FOCUS FOR AI AND ML, WHERE AREAS
LIKE IMAGING BUT GIVEN THE HAD
NHLBI'S MISSION, I WOULD ALSO
CALL OUT, BASICALLY AI ML FOR
PHYSIOLOGIC SIGNAL ANALYSIS.
I KNOW I SEE IN OUR REPOSITORY
REALLY DOZENS OF PEOPLE WORLD
WIDE NOW TAKING ADVANTAGE OF THE
-- YOU KNOW COMPLEX DYNAMIC
INFORMATION WHETHER IT'S TIME
SERIES DATA, WHETHER IT'S FROM
AN ECG OR TRACING OR OVERNIGHT
SLEEP STUDY THAT'S REALLY
BEGINNING TO REVOLUTIONIZE
REALLY EVEN HOW WE DIAGNOSE
SLEEP DISORDERS, CIRCADIAN
RHYTHM PROBLEMS AND THEN PREDICT
CARDIOVASCULAR OUTCOMES.
>> THANK YOU VERY MUCH FOR THAT
RECOMMENDATION.
ANYONE ELSE HAVE ANY THOUGHTS?
HERE?
>> HOPE YOU'LL GIVE US
SUGGESTIONS LIKE SUSAN JUST DID
AND BE SURE THAT WHAT'S MISSING,
SO LESS ABOUT CONCERNS MORE WHAT
ARE YOUR INPUTS AND SUGGESTIONS
AND THINGS WE MAY NOT HAVE
THOUGHT OF.
OVER.
>> THANK YOU FOR THAT, YES, SO
YES, ANYTHING THAT YOU THINK
THAT WE SHOULD INCORPORATE OR AT
LEAST CONSIDER AS WE'RE MOVING
FORWARD.
OR ANY CONCERNS WITH MOVING
FORWARD, BUT I HEAR THAT THEIR
SEEMS TO BE ENTHUSIASM BUT WE
WANT TO MAKE SURE THAT WE'RE AT
THE OUTSET, WE'RE STARTING OFF
WITH THE BROADEST PERSPECTIVE ON
WHAT WE'RE TRYING TO ACCOMPLISH.
>> DR. STEIN?
>> YOU'RE MUTED.
>> THANK YOU.
SO THIS SEEMS TO BE MUCH MORE
EXTERNALLY FOCUSED AND MOVING
THE SCIENCE FORWARD, I'M
WONDERING IS ANY PART OF THIS
ALSO LOOKING AT INTERNALLY WE DO
SEE THE ADMINISTRATIVE WORK LOAD
FOR EITHER PIs OR THE NIH WORK
FLOW AS PART OF THIS MANDATE?
>> WELL I THINK INTERNALLY OUR
INTERNAL GROUP IS LOOKING AT
THAT, WE HAVE AN INTERNAL FACING
DISCUSSING HOW WE SHOULD MOVE
FORWARD AND LOOKING INTERNALLY,
BUT WE'RE LOOKING THIS GROUP
WOULD REALLY BE ESTABLISHED I
THINK MORE IN TERMINGS OF
EXTERNALLY FACING, OUTWARD
FACING IN TERMS OF WHERE WE NEED
TO GO WITH THE RESEARCH, WE'RE
TRYING TO COVER BOTH AND NOT
EITHER OR.
YES, LET'S SEE, DOCTOR?
>> YOU WANT TO COMMENT?
>> SO EXCELLENT POINT, JUST TO
EMBELLISH ON THERESA'S ANSWER,
THERE MIGHT HAVE BEEN A HINT OF
THAT IN SEAN'S COMMENTS THAT
OBVIOUSLY FROM AN NHLBI
STANDPOINT ANY APPROACH TO THOSE
KIND OF OPERATIONAL
ADMINISTRATIVE APPLICATIONS OF
AI, WE WOULD WANT TO DO AS AN
NIH ENTERPRISE, NOT AS AN NHLBI
SPECIFIC 1 AND AS HE KIND OF
ALLUDED TO THOSE EFFORTS ARE
HAPPENING.
THERE ARE A LOT OF THINGS THAT
ARE BEING CONTEMPLATED AND YOU
SAW HIM HESITATE, BUT OBVIOUSLY
THERE ARE THINGS THAT ARE BEING
PILOTED INTERNALLY, BUT THE HOPE
AND ANTICIPATION WOULD BE WE
WOULD BE CREATING CLOUD BASED
RESOURCES ACCESSIBLE BY THE
EXTRAMURAL COMMUNITY THAT COULD
LEVERAGE THAT WITH ALL THOSE
ISSUES OF STANDARDS, ETHICS,
RESPONSIBILITY, SECURITY,
LEAKINESS, AND SO, THOSE
THOUGHTS AND HOW TO DO THAT ARE
ACTIVELY UNDERWAY.
HE KIND OF KEPT IT VERY MODEST
IN TERMS OF WHAT'S ACTUALLY
ALREADY BEEN LAUNCHED BUT YOU
CAN SEE THE TRAJECTORY AND TO
YOUR POINT, THOSE THINGS WOULD
BE IMPORTANT, RIGHT IF WE'RE
HAVING A STANDARDIZED WAY OF
EVALUATING THE REVIEW OR PLANS,
YOU WANT TO DO THAT IN A
CONSISTENT WAY AND KEEP
VALIDATING THAT IT'S WORKING.
SO, INDEED, YOU KNOW SOME OF
THOSE THINGS ARE BEING PILOTED
FOR CSR AS WE SPEAK, SO YES,
THIS IS BEING TESTED AND PILOTED
IN A WAY THAT COULD AFFECT THE
EXTRAMURAL COMMUNITY LEVERAGING
THE TOOLS AND TECHNOLOGIES AND
HOPEFULLY THIS WAYS THAT MIGHT
STREAMLINE THE PROCESSES
OPERATIONALLY FOR EVERYBODY IN
THE ECOSYSTEM, I HOPE THAT
HELPS.
>> ANOTHER HAND UP?
>> I THINK I HAD -- I DON'T KNOW
BUT I THINK THAT ADDRESSED A LOT
OF WHAT I WAS THINKING.
A LOT OF WHAT I WAS THINKING BUT
I THINK THIS WAS HINTED AT BUT
YOU KNOW I AM TRYING TO MAKE
SURE THIS IS ALIGNED WITH
EVERYTHING ELSE THAT'S HAPPENING
AT THE NIH.
WE ALWAYS HATE TO SEE THIS THING
WHERE EVERY IC IS DOING
SOMETHING DIFFERENTLY AND THAT
ALIGNMENT AND INITIATIVES I
THINK WILL BE REALLY HELPFUL BUT
OVERALL, AGAIN, VERY HAPPY TO
SEE THIS, SOMETHING VERY
IMPORTANT TO DO THIS, ANYTHING
THIS CAN BE DONE TO IMPROVE
EFFICIENCY IS REALLY GREAT.
SO CONGRATS.
GREAT JOB.
>> THANK YOU.
AGAIN, 1 OF MY POINTS ON THE
SLIDE WAS TO AVOID REDUNDANT, WE
ARE PAYING ATTENTION TO WHAT'S
HAPPENING AGENCY WIDE, ACB,
WORKING GROUP, ET CETERA.
SO THANK YOU.
>> DOCTOR?
>> I DON'T KNOW IF IT'S WITHIN
SCOPE BUT THINKING ABOUT HOW TO
EFFECTIVELY COMMUNICATE SCIENCE
AND SCIENTIFIC FINDINGS TO OUR
DIVERSE U.S. AUDIENCE OF
TAXPAYERS WHO SUPPORT OUR
RESEARCH UTILIZING AI, COULD BE
REALLY VERY INSTRUMENTAL AS
WELL.
>> AGAIN, ANOTHER GREAT POINT
AND 1 OF THE THINGS THAT MEEOF
THE OF YOU INTUITIVELY KNOW, BUT
IN TERMS OF VISITS TO THE NHLBI
WEBSITES IT'S ACTUALLY NOT FOR
OUR NOFOs AND RESEARCH
OPPORTUNITIES IT'S FOR OUR
HEALTH TOPIC SECTION WHICH, YOU
KNOW THE GENERAL PUBLIC WANTS TO
KNOW, WHAT IS HIGH BLOOD
PRESSURE OR SOMEBODY DOCTOR JUST
TOLD ME I HAVE COPD, WHAT IS
THAT?
SO ACTUALLY 1 OF THE THINGS
BEING CONSIDERED IN TERMS OF
PILOTING AS YOU MIGHT IMAGINE IS
THOSE ARE THINGS THAT A SIRI
LIKE THING OR CONSIST ANT COULD
START TO ADD AND PROBABLY THAT'S
COMING TO AN EHR NEAR YOU AS
WELL, SO GETTING OUT IN FRONT OF
THIS, AND BEING SURE THAT IT'S
EVIDENCE BASED, SCIENTIFICALLY
BASED, A WAY TO BE VALIDATED, A
WAY TO BE SURE THAT THE ANSWERS
TO THOSE QUERIES, ARE NOT ONLY
ACCURATE BUT AS YOU KNOW, CAN
YOU CALIBRATE SOME OF THESE CHAT
BOTS TO THE LEVEL OF EDUCATION
PERHAPS.
I KNOW WE HAVE -- THERE MAY BE
NUANCANCES OF CULTURAL
SENSITIVITY OR APPROPRIATENESS
WHERE THERE MIGHT BE FURTHER
TAILORING NECESSARY TO CONVEY
THE RIGHT MEANING AND EVEN
ENGAGE IN DIALOGUE, SO I THINK
THERE ARE ELEMENTS WHERE THE
TAILORING AND CUSTOMIZATION AND
INSURING AGAIN, RESPONSIBLE AI
IS BEING PURSUED, STARTS TO GET
INTERWOVEN TO ALMOST EVERYTHING
WE DO, AND IT'S POTENTIALLY
EVERYWHERE AND INSURING THAT
IT'S -- AGAIN ALIGN WIDE OUR
VALUES AND OUR PARTICULAR
PRINCIPLES, I THINK WILL BE
IMPORTANT AND THAT'S ASPECT WE
HAVE TO DO AS A COMMUNITY.
SO THAT'S WHY WE FEEL IT'S
IMPORTANT TO HAVE A COUNCIL
WORKING GROUP BECAUSE THESE ARE
COMPLEX QUESTIONS AND IT GOES
THROUGHOUT OUR MISSION AND I
THINK IT'S SOMETHING WE HAVE TO
BE VIGILANT ADAPTIVE AND NIMBLE
ABOUT CERTAINLY OVER THIS NEXT
FEW YEARS AS TECHNOLOGY REALLY
JUST EXPLODES INTO OUR SPACES
AND AFFECTS EVERYTHING.
SO APPRECIATE THAT COMMENT,
OVER.
>> ANY ADDITIONAL THOUGHTS ON
THIS WORKING GROUP.
SO IF NO OTHER COMMENTS DO WE
HAVE CONCURRENCE TO MOVE FORWARD
WITH THE COUNCIL, WE HAVE A
MOTION TO MOVE FORWARD?
>> SO MOVE.
>> SECOND.
>> OKAY.
ALL APPROVE?
>> AYE.
>> AI.
>> [LAUGHTER]
>> ANY OPPOSE?
>> NICE PICK ME UP AFTER LUNCH?
ANY OPPOSE?
ANY ABSTENTIONS?
OKAY.
THANK YOU VERY MUCH FOR YOUR
FEEDBACK.
NOW MOVING TO THE FINAL STAGE OF
THE OPEN SESSION WHERE I WILL
COVER THE DELEGATED AUTHORITIES
WHICH WE COVER ANNUALLY WITH THE
COUNCIL MEMBERS.
WE HAVE THE SLIDE.
OKAY.
SO AN ANNUAL BASES WE REVIEW THE
DELEGATED AUTHORITIES OF NHLBI
WITH THE SUMMARY OF COUNCIL.
THE SUMMARY OF THOSE AUTHORITIES
ARE HERE, WHAT WE ARE PRESENTING
BEFORE YOU HAVE NOT CHANGED
SINCE LAST YEAR, WE WANT TO
AGAIN AS LISTED HERE THE ITEMS
ARE TO TAKE ADMINISTRATIVE
ACTIONS, AS APPROPRIATE TO USE
SCIENTIFIC AND PROFESSIONAL
SERVICES OF NOT MORE THAN A
HUNDRED SPECIAL EXPERTS
APPOINTED BY THE DIRECTOR,
EXPEDITE COUNCIL CONCURRENCE
USING PROCEDURES OUTLINED IN BY
AUTHORITIES, PROGRAM PLANS AND
BLOCK ACTIONS, MAKE CERTAIN
ADMINISTRATIVE DECISIONS SUCH AS
SELECTION AND FUNDING AND
PETEING GRANT APPLICATIONS IN
THE EVENT OF A FEDDERALLY
DECLARED EMERGENCY,
DELATWALLEIGATIONS OF ECB IF
ENBLOCK PROCEDURES ARE NOT
EASIBLE.
THIS IS A HIGH LEVEL OVERVIEW,
WE HAVE RESOURCED DOCUMENTS BUT
WE ARE REQUIRED TO BRING THIS TO
YOUR ATTENTION EACH YEAR AND GET
YOUR CONCURRENCE THAT THESE ARE
NO CHANGES OR ANY CONCERNS YOU
HAVE WITH THE CURRENT DELICATED
AUTHORITIES TO THE NHLBI.
WE CAN STOP SHARING THE SLIDES.
DO WE HAVE ANY QUESTIONS OR
CONCERNS?
OKAY, HEARING AND SEEING NO
HANDS AND HEARING NO COMMENTS
THEN WE WILL MOVE FORWARD AND
CONTINUE WITH OUR CURRENT
DELEGATED AUTHORITIES UNCHANGED
FROM LAST YEAR.
THANK YOU AND THIS NOW CONCLUDES
THE OPEN SESSION OF COUNCIL SO I
WILL TURN IT OVER TO DR. GIBBONS
FOR ANY FINAL COMMENTS.
>> WELL, THANK YOU ALL AGAIN FOR
SHARING AND WORKING THROUGH THIS
VIRTUAL SESSION.
IT'S AN ATTEMPT AGAIN TO BE
EFFICIENT USERS OF YOUR TIME AND
HOPEFULLY THIS WAS AN EFFECTIVE
APPROACH.
WE ARE ALWAYS OPEN TO FEEDBACK.
WE APPRECIATED THE DIALOGUE, THE
INPUT WE RECEIVED AND INDEED
IT'S HAVING AN IMPORTANT SHAPING
AFFECT ON OUR PLANS, ALSO
APPRECIATE YOUR ENDORSEMENT OF
THE AI WORKING GROUP.
THIS IS AN IMPORTANT THING THAT
I THINK IN PARTICULAR, THE NEXT
COUPLE OF YEARS, WILL BE A VITAL
AND CENTRAL ELEMENT OF A LOT OF
OUR ACTIVITIES SO WE LOOK
FORWARD TO YOUR ACTIVE
ENGAGEMENT IN THAT AS WELL, AND
HOPEFULLY, YOU WILL ALSO
APPRECIATE THE COMMITMENT TO GET
US BACK TO DOING OUR MISSION AND
THE BUSINESS OF NIH AND SO, WE
WON'T BE CONTINUOUSLY
DISSTRACTED AND GET BACK TO FOLK
UING ON WHAT WE DO -- FOCUSING
ON WHAT WE ALL DO TOGETHER SO
THANK YOU AGAIN FOR YOUR
ATTENTION AND I WILL BRING THIS
310th MEETING TO ADJOURNMENT.
>> THANK YOU EVERYONE.